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Effects of Subcutaneous Adipose Tissue on Metabolic Health in Obesity 
By 
Douglas William Van Pelt Jr. 
 
Chair: Jeffrey F. Horowitz 
 
 Adipose tissue metabolic function, structure, and overall adipose tissue “health” are key 
mediators of obesity-related cardio-metabolic abnormalities, including insulin resistance, which 
plays a central role in the development of many chronic diseases.  Excessive fatty acid release 
from subcutaneous adipose tissue (SAT) is one of the most important factors underlying insulin 
resistance.  Other major factors in SAT that are linked to abnormalities in metabolic health 
include adipose tissue inflammation, extracellular matrix composition and structure, 
adipogenesis, and angiogenesis. However, despite some recent advances, understanding the role 
of SAT on metabolic health in human obesity is rather limited.  In addition, although exercise is 
often-prescribed in attempt to improve cardio-metabolic health, it remains unclear whether 
exercise can impart adaptations in adipose tissue that contribute to improvements in whole-body 
metabolic health in obesity.  The overall objectives of this dissertation were to assess how 
subcutaneous adipose tissue may contribute to whole-body metabolic outcomes in obesity, and 
whether exercise can modify adipose tissue in a manner that improves markers of metabolic 
health. In STUDY #1, insulin sensitivity (frequently sampled intravenous tolerance test; 
FSIVGTT) and systemic fatty acid rate of appearance in plasma (FA Ra; stable isotope dilution 
methods) were measured in 21 obese adults (BMI = 34±1 kg/m2; age = 30±1 yrs), and FA Ra 
was found to be an important determinant of insulin resistance (R2=0.21; P=0.04).  In addition, 
skeletal muscle samples collected from subjects who were insulin resistant had higher markers of 
skeletal muscle inflammation known to inhibit insulin signaling (e.g., phosphorylated c-Jun N-
terminal kinase) compared with the more insulin sensitive subjects (P<0.05). Given the 
importance of basal fatty acid mobilization rates on insulin resistance (as reported in STUDY 
#1), STUDY #2 aimed to identify factors in SAT that may underlie low vs. high rates of fatty 
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acid mobilization in obese adults. FA Ra (stable isotope dilution methods) and insulin sensitivity 
(hyperinsulinemic-euglycemic clamp) were measured in 30 obese adults (BMI = 38±1 kg/m2; 
age = 30±2 yrs). Confirming results from STUDY #1, insulin sensitivity was inversely 
proportional to FA Ra (R2=0.50; P<0.001).  In addition, SAT from subjects with low FA Ra had 
significantly lower (P<0.05) markers of lipase activation and higher abundance (P<0.05) of 
glycerol-3-phosphate acyltransferase (GPAT), which is a primary enzyme regulating fatty acid 
esterification. Microarray and pathway analysis also indicated lower fibrosis and lower 
SAPK/JNK pathway activation in obese adults with low FA Ra compared to those with high FA 
Ra (P<0.05). Finally, in STUDY #3, overweight-to-obese adults who exercise regularly 
(ACTIVE: BMI 29±1 kg/m2; age = 27±1 yr; n=8) or were sedentary (SED: BMI 27±1 kg/m2; age 
= 27±2 yr; n=12) were recruited to examine the effects of exercise (chronic and acute) on 
adipose tissue. In both groups, acute exercise increased SAT mRNA expression of VEGFA, an 
important regulator of angiogenic processes.  In line with this finding, SAT from ACTIVE 
subjects had a higher mRNA expression of the endothelial cell marker, CD31, compared with 
SED, suggesting regular exposure to exercise may increase SAT capillarization. Together, 
findings from this dissertation provide novel insights into how alterations in SAT structure and 
metabolic function can greatly impact insulin resistance, and whole-body metabolic health. 
These data may help lead to development of treatments (lifestyle or pharmaceutical) to target and 
















 Statement of the Problem 
 
Approximately one-third of adults in the United States are classified as obese (1).  The high 
prevalence of obesity is alarming since obesity is a leading risk factor for the development of 
many health complications, such as Type 2 Diabetes Mellitus (T2DM) and cardiovascular 
disease (CVD), causing obese persons to have increased mortality compared with lean, healthy 
individuals (2-5). Furthermore, obesity-related diseases and other cardio-metabolic health 
complications have placed an enormous financial burden on the U.S. healthcare system by 
accounting for an estimated 5% to 10% of direct medical costs within the US healthcare system 
(6, 7).  Research focusing on the causes and consequences of obesity-related diseases, and 
optimizing interventions targeting key factors underlying these diseases may alleviate much of 
the negative health outcomes of obesity.   
 
No single metabolic abnormality is responsible for the elevated cardio-metabolic disease risk in 
obesity, but the very high prevalence of insulin resistance in obesity is of particular interest (8, 
9).  Insulin resistance is defined as a subnormal response to a physiological dose of insulin, and 
can result in impaired skeletal muscle glucose uptake, elevated hepatic glucose production, and 
reduced inhibition of adipose tissue lipolysis (10, 11).  Epidemiological as well as longitudinal 
studies indicate that insulin resistance is a strong predictor of CVD and mortality (12-14).  
Conversely, a relatively small subset of obese adults who are not insulin resistant appear to be 
protected from developing many chronic cardio-metabolic health complications.  Data from the 
National Health and Nutrition Examination Survey (NHANES) indicates that as many as one-
third of U.S. obese adults remain metabolically healthy (e.g. not insulin resistant) (15) , and these 
“insulin sensitive” obese adults often have mortality rates equivalent to lean, healthy individuals 
(15-17).  It is not known why some obese adults remain insulin sensitive while most become 
insulin resistant, despite being very similar in terms of the magnitude and distribution of their 
body fat.  A greater understanding of the physiological mechanisms that “protect” some obese 
individuals from insulin resistance may provide valuable insight into potential treatments and 





The overall health and function of adipose tissue is now recognized an important factor dictating 
obesity-related metabolic outcomes. Over the past few decades our knowledge about the 
metabolic function of adipose tissue has expanded from being a rather benign storage site for 
excess energy to the current understanding that it serves important endocrine and paracrine 
functions by producing and secreting many different peptides (18).  The secretion of adipocyte 
derived factors has been implicated as an important component of obesity-induced insulin 
resistance, however, it is important to acknowledge that the primary role of adipose tissue is to 
store energy, and complications associated with the regulation of lipid storage within adipose 
tissue can have profound metabolic consequences (18-20).  Various elements of adipose tissue 
structure and function have been postulated to be important mediators of “adipose tissue health” 
and lipid storage capacity, including cell size (21), adipogenesis (22), angiogenesis(23), 
extracellular matrix dynamics (24, 25), and inflammation (26, 27). The coordination and 
response of these adipose tissue biological processes may determine adipose tissue health and 
function and thus, overall metabolic health in obesity  
 
A major premise of my dissertation is that factors effecting fatty acid flux (such as factors 
mentioned above) in adipose tissue can play an important role in dictating whole body metabolic 
health (28-30). In agreement, a major factor underlying insulin resistance in obesity is excessive 
fatty acid mobilization from adipose tissue (31-34). Lowering fatty acid mobilization in obese 
adults through pharmacological treatments or weight loss, decreases insulin resistance (35-37).  
Alternatively, artificially elevating fatty acid mobilization in lean, healthy volunteers (via lipid 
infusion) profoundly impairs insulin-mediated glucose uptake (38, 39). High rates of fatty acid 
mobilization into the systemic circulation (referred to here as “fatty acid availability”) and a 
resultant high rate of fatty acid uptake into insulin-sensitive tissues, like skeletal muscle, can 
directly and indirectly interfere with the insulin signaling cascade (40, 41).  Although fatty acid 
availability is typically very high in obesity (32), there is still considerable variability in fatty 
acid mobilization from adipose tissue, even among a seemingly homogenous population of obese 
adults (42).  However, the role that this variability in fatty acid availability has on determining 
the degree of insulin resistance in obese adults is not clear.  Moreover, it is not known how some 
obese adults can maintain a relatively low rate of systemic fatty acid mobilization, while it is 
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rather high in most obese adults.  Determining whether variations of fatty acid availability dictate 
skeletal muscle inflammation and insulin resistance – and expanding our understanding about 
factors underlying the variability in fatty acid mobilization from adipose tissue will provide 
important insights into potential targets for pharmacological and/or lifestyle interventions. In 
turn, pharmacological and/or clinical interventions targeting these mechanisms within adipose 
tissue may help prevent or treat insulin resistance in obesity.   
 
Finally, exercise is often prescribed in attempt to improve metabolic health in obesity, but the 
mechanisms underlying the insulin sensitizing effects of exercise are still not completely 
understood.  Most of the recognized mechanisms for the improvement in insulin sensitivity after 
exercise have been isolated to skeletal muscle.  Indeed, reductions in muscle glycogen content 
and alterations in fatty acid partitioning within skeletal muscle are known mechanisms that 
enhance insulin action after each session of exercise (43-45).  Surprisingly, very little is known 
about the effects of exercise on adipose tissue metabolism and lipid storage.  Moreover, it is 
unclear whether exercise can impact factors regulating inflammation, angiogenesis, extracellular 
matrix structure and composition, or adipogenesis in the adipose tissue.  Available evidence in 
rodent models suggest exercise may confer beneficial metabolic adaptations by reducing adipose 
tissue inflammation, fibrosis, as well as fat cell size (46-48), but evidence in human adipose 
tissue is lacking. Because exercise training is often found not to enhance insulin sensitivity 
beyond a day or so after the most recent exercise session - it might be assumed that any exercise-
induced adaptations in adipose tissue may not be important for long-term improvements in 
metabolic health in humans. However, exercise-mediated effects on adipose tissue structure and 
metabolic function may only be apparent during periods of nutrient surplus.  The ability to 
expand adipose tissue during periods of weight gain without excess fibrosis and inflammation 
may confer long-term protection against insulin resistance.  The overall hypothesis for the third 
study of my dissertation is that each session of exercise “primes” adipose tissue for more 
effective energy storage through changes in adipose tissue inflammation, extracellular matrix, 
angiogenic capacity, and/or adipogenic capacity.  The key first step in advancing our 
understanding about the role of exercise on adipose tissue structure and metabolic function is to 




The studies of my dissertation were designed to address the following specific aims: 
 
1. Determine if the degree of fatty acid mobilization dictates the observed variability in 
insulin resistance in obesity. 
2. Investigate whether obese adults with low rates of fatty acid mobilization exhibit 
differences in adipose tissue structure and metabolic function compared to obese adults 
with elevated fatty acid mobilization. 
3. Characterize the effects of a single session of aerobic exercise on factors regulating 
adipose tissue structure, metabolic function, and inflammation. 
 
The overall goal of my dissertation was to investigate the physiological mechanisms within 
adipose tissue that may protect obese individuals from developing insulin resistance. The 
information gained from my dissertation studies expands our understanding of adipose tissue 
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 Review of Literature 
 
Approximately one-third of adults in the United States are considered obese (1).  This has 
become a major public health concern, as obesity is associated with the development of 
metabolic, cardiovascular, and other diseases such as Type 2 Diabetes Mellitus (T2DM), 
cardiovascular disease (CVD), stroke, and cancer (2-4).  In addition to the tremendous impact 
these diseases have on the lives of the patients and their families, the high rates of obesity-
induced disease have placed an enormous economic burden on the healthcare system.  Increasing 
body mass index (BMI) is associated with higher direct healthcare costs, with obesity-related 
medical expenses now accounting for 5% to 10% of U.S. healthcare spending (5, 6).  
Furthermore, there are indirect costs of obesity due to the reduced workplace productivity and 
early mortality that impedes workplace function and income (5, 7).  The development of excess 
fat mass in obesity is central to chronic metabolic health complications and most obesity-related 
diseases can be prevented or even reversed with weight loss.  However, rates of successful 
weight loss in obese adults remain very low (8); thus, research is needed to find alternative 
therapeutic and preventative options for obesity-related diseases. 
Obesity is associated with insulin resistance, which is defined as a subnormal response to a 
physiological dose of insulin (9, 10).  Insulin plays a critical role in the regulation of blood 
glucose, as well as many other vital metabolic processes (e.g., lipolytic rate, protein synthesis, 
etc.), and chronic impairments in the ability to respond effectively to insulin can lead to the 
development of metabolic and cardiovascular disease (11-13).  For example, type 2 diabetes is 
defined as a chronic elevation of blood glucose, caused largely by skeletal muscle and hepatic 
insulin resistance.  Certainly there are other obesity-related abnormalities that contribute to the 
development of chronic diseases in obesity, but it is clear that strategies aimed at attenuating 
insulin resistance can play a key role in preserving metabolic health.  
Although the vast majority obese adults are insulin resistant with high risk for chronic 
disease, not all obese adults develop insulin resistance or exhibit metabolic dysfunction.  It has 
been reported that as many as one-third of obese adults can be classified as “metabolically 
normal” - with insulin sensitivity similar to lean, healthy adults (14-16).  Furthermore, obese 
adults that remain insulin sensitive appear to have mortality rates equivalent to lean, healthy 
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adults (17, 18).  It should not be overlooked that most obese adults do indeed develop insulin 
resistance and metabolic disease, but obese adults who remain insulin sensitive have become a 
well-recognized group for investigating factors that may “protect” against obesity-related insulin 
resistance.  In this review, I will focus my discussion on the current knowledge regarding the role 
that adipose tissue structure, function and metabolism may play in the development of obesity-
related insulin resistance and potential adipose tissue characteristics that may “protect” some 
obese adults from developing insulin resistance.  Specifically, this review will describe the 
effects of fatty acid availability as a key mediator of obesity-related insulin resistance and 
summarize factors in adipose tissue that may be important for dictating the storage and release of 
fatty acids, including adipose tissue components related to inflammation, immune cell function, 
and properties of the extracellular matrix.  The review will also discuss the current knowledge of 
the acute and chronic effects of exercise on adipose tissue lipid metabolism, structure, and 
inflammatory processes.   
 
FACTORS REGULATING INSULIN RESISTANCE IN OBESITY 
Abnormalities in many different tissues contribute to the development of metabolic 
complications in obesity.  The liver plays a vital role in blood glucose control through storage 
and production of glucose, and dysregulation of hepatic glucose metabolism can lead to 
hyperglycemia and impaired overall metabolic health (19, 20).  As such, hepatic insulin 
resistance is a common feature in the pathology of Type 2 Diabetics, which exacerbates their 
chronic hyperglycemia.  However, while the liver is certainly important in dictating overall 
metabolic health, it has been demonstrated that skeletal muscle is the primary site of insulin 
mediated glucose disposal (21).  Therefore, impaired insulin action in skeletal muscle is 
responsible for most of the systemic insulin resistance commonly found in obesity.  The control 
of blood glucose uptake in skeletal muscle is regulated by a well-known complex signaling 
pathway initiated when insulin binds to its receptor, and ultimately results in the translocation of 
the glucose transporter, GLUT 4 to the membrane of the cell (See Figure 2-1A).  Binding of 
insulin to its receptor leads to tyrosine phosphorylation of the insulin receptor substrate 1 (IRS-1) 
and subsequent downstream signaling and interaction with phosphatidylinositol 3-kinase (PI3K) 
(22-24).  This leads to signaling through PKB/Akt and eventually phosphorylates AS160 (Akt 
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substrate of 160kD), inhibiting the Rab-GTPase-activating protein (Rab-GAP) and releases 
GLUT4 from its intracellular pool for translocation to the myocyte membrane (25, 26).  
Disruption of any one or more steps of this signaling pathway can lead to insulin resistance as 
well as other metabolic abnormalities (27-29). 
The insulin resistance that occurs in skeletal muscle and liver is due in part to the excessive 
systemic fatty acid availability commonly found in obesity.  To demonstrate the potent effects of 
elevated fatty acid availability on insulin resistance, several studies report profound insulin 
resistance in healthy, lean subjects after just a few hours of a lipid and heparin infusion to mimic 
the high rates of fatty acid availability found in obesity (30, 31).  Conversely, drugs that lower 
systemic fatty acid availability in obese adults have been found to reverse insulin resistance (32, 
33).  Much of the excessive fatty acid availability that is common in obesity is due to 
inadequately sequestering and storing excess fatty acids as triglycerides within subcutaneous 
adipose tissue (34).  This phenomenon is demonstrated in patients with lipodystrophy, which is a 
genetic disorder characterized by a lack of subcutaneous adipose tissue formation, and an 
extraordinarily low capacity to store fatty acids as triglycerides (TG) (35).  Humans with 
lipodystrophy appear very lean, yet they develop extreme insulin resistance in conjunction with 
elevated plasma fatty acids and lipid deposition in the skeletal muscle and liver (36).  
Lipodystrophic mice develop similar metabolic complications, however, these complications 
(e.g. insulin resistance, ectopic lipid deposition, etc.) have been found to be reversed with 
transplantation of functioning subcutaneous adipose tissue (37).  Although it may seem counter-
intuitive, the ability to expand subcutaneous adipose tissue to accommodate nutrient oversupply 
during periods of weight gain may actually help prevent insulin resistance by enhancing the 
capacity to sequester fatty acids-thereby preventing excess fatty acid release and ectopic lipid 
deposition in insulin sensitive tissues (34). 
High fatty acid availability has been linked to excess skeletal muscle uptake of fatty acids 
and the accumulation of lipid intermediates within the skeletal muscle, such as diacylglycerol 
(DAG), ceramides, and long-chain fatty acyl-CoAs (29, 38).  DAG, as well as ceramides, and 
long-chain fatty Acyl-CoAs can impede insulin signaling by interacting with serine kinases 
protein kinase C-θ, c-Jun N-terminal kinase (JNK), Inhibitor of kB (IkB) kinase (IKK), and 
nuclear factor κB (NFκB), which can directly and indirectly interfere with the insulin signaling 
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cascade (29, 39-41) (See Figure 2-1B).  The serine kinases PKC- θ, JNK and IKK are related to 
insulin resistance in obesity and mechanistic studies have revealed their roles in directly 
inhibiting insulin signaling through phosphorylation of serine residues (Ser307, Ser1101) on 
IRS-1 (42-44), which inhibits the ability to become phosphorylated at the necessary tyrosine sites 
required for downstream signaling(27, 28).  Moreover, JNK and IKK are involved in many cell 
signaling pathways and increased phosphorylation and activity of these proteins may decrease 
the inhibition of NFκB and increase the transcription of inflammatory cytokines (e.g. TNFα, IL-
6) that may also interfere with insulin action (45, 46).  Ceramides can also inhibit insulin action 
through interaction with protein phosphatase 2A (PP2A) and protein kinase C-ζ (PKC- ζ), which 
prevent the stimulation of PKB/Akt- a serine/threonine kinase that is a crucial step in the 
translation of insulin binding and GLUT 4 translocation to the membrane (47, 48).  Interestingly, 
although intramyocellular triacylglycerol (IMTG) concentration is also commonly found to be 
elevated in obese insulin resistant adults (49), the accumulation of IMTG does seem to mediate 
the level of insulin resistance (50).  This is demonstrated by the “athlete’s paradox”, in which 
athlete’s with good metabolic health exhibit elevated levels of IMTG similar to insulin resistant 
obese adults (51).   In all, much of the insulin resistance observed in obesity is a consequence of 













Figure 2-1A: Lipid metabolic fates and insulin signaling.  As fatty acids enter the skeletal muscle, most are 
either oxidized for production of energy in the mitochondria, or synthesized into triacylycerol and/or fatty acid 
intermediates (i.e. diacylglycerol (DAG), ceramides).  Normal insulin signaling involves binding of insulin to its 
receptor and phosphorylation of insulin receptor substrate (IRS) on tyrosine residues.  Downstream signaling 
events initiate the translocation of GLUT4 to the cell surface membrane and allow for increased glucose uptake.  
Figure 2-1B: Lipid induced insulin resistance in obesity.  Excess fatty acid availability and uptake into skeletal 
muscle in during obesity increases the abundance of intramuscular triglyceride and fatty acid intermediates.  
Elevated DAG and ceramides increase the activity of serine kinases (i.e. JNK and IKK) that interfere with normal 
insulin signaling and reduce GLUT4 translocation to the cell membrane.  
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SUBCUTANEOUS ADIPOSE TISSUE IS A KEY MEDIATOR OF FATTY ACID 
AVAILABILITY AND INSULIN RESISTANCE IN OBESITY 
The ectopic lipid deposition that interferes with insulin signaling is a consequence of the 
excess release of fatty acids from adipose tissue depots throughout the body.  The accumulation 
of visceral adipose tissue is often linked with the severity of cardio-metabolic disease risk (52), 
however, the excess accumulation of visceral fat is most likely a result of the subcutaneous 
adipose tissue’s inability to properly store the excess nutrients.  Nielsen et al. demonstrated that 
approximately 90% of all fatty acids in the systemic circulation are derived from subcutaneous 
adipose tissue, with nearly 70% of these fatty acids coming from abdominal subcutaneous 
adipose tissue (53).  Moreover, despite the anatomical proximity of visceral adipose tissue with 
the liver, the vast majority of fatty acids in the hepatic circulation are also derived from 
abdominal subcutaneous adipose tissue (53).  These data demonstrate the importance of 
subcutaneous adipose tissue in the control of fatty acid mobilization and subsequently, the 
control of lipid deposition and insulin sensitivity in skeletal muscle.  Human studies using 
deuterated water (2H2O) to track long-term turnover and storage of TG have found that TG 
synthesis and storage is impaired in the subcutaneous adipose tissue of insulin-resistant obese 
individuals compared with obese adults who maintain normal insulin sensitivity (54).  
Obviously, the regulation of lipolysis and esterification will modulate the degree of fatty acid 
release from adipose tissue and determine TG storage.  There are several other factors within the 
subcutaneous adipose tissue that contribute to the capacity for fatty acid uptake and storage such 
as expansion of adipose tissue, fatty acid transport, and adipose tissue blood flow.  Additionally, 
obese adults who remain healthy exhibit adipose tissue characteristics indicative of improved 
lipid storage and handling, such as increased adipocyte number, lower inflammation, and lower 
ectopic lipid deposition (14, 55, 56). 
 
Lipolysis, esterification, and fatty acid transport 
Regulation of triglyceride storage and release from subcutaneous adipose tissue is 
multifaceted, involving coordinated activities of factors activating triglyceride hydrolysis, 
esterification, and fatty acid trafficking.  Lipolysis involves the hydrolysis of TG fatty acid-
glycerol ester bonds that can ultimately lead to release of non-esterified fatty acids (NEFA) from 
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the lipid droplet and into the bloodstream for delivery as an energy substrate to peripheral 
tissues.  It is a process activated through multiple mechanisms including catecholamines and 
other hormones and peptides (e.g. naturetic peptides, growth hormone, and cytokines), and 
results in the sequential hydrolysis of three fatty acid-glycerol ester bonds (57).  In contrast, 
insulin potently suppresses lipolysis by inhibiting the activity of essential lipases (58, 59).  
Adipose triglyceride lipase (ATGL) has been identified as a major lipase necessary for the 
removal of the first fatty acid-glycerol ester bond (60), while hormone sensitive lipase (HSL) and 
monoglyceride lipase (MGL) predominantly hydrolyze diacylglycerol (DAG) and monoglycerol 
(MG), respectively (61, 62).  Perturbations in the expression, abundance, and activation of these 
lipases controlling lipolysis may dictate the variability in fatty-acid mobilization and as a result, 
may impact whole-body insulin resistance.  For example, mice lacking ATGL develop larger fat 
mass compared to wild-type (WT) mice along with increased TG deposition in skeletal muscle, 
however, the increased storage of fatty acids as neutral lipids and the low rate of fatty acid 
mobilization improved insulin sensitivity in these mice (63).  Similarly, Girousse et al. 
demonstrated that partial inhibition of lipolysis through pharmacological or genetic manipulation 
of HSL, without alterations in fat mass, resulted in lower fatty acid mobilization and improved 
insulin sensitivity compared to WT mice in diet induced obesity (64).  Lower markers of 
lipolysis have also been reported to correlate with reduced indices of insulin resistance, 
independent of fat mass, in obese humans (64).  
Regulation of the rate of triacylglycerol synthesis (i.e., esterification) in adipose tissue can 
also contribute to the magnitude of systemic fatty acid mobilization.  Two main enzymes, 
mitochondrial glycerol-3-phosphate (mGPAT) and diacylglycerol acyltransferase (DGAT), 
catalyze the first and final steps in triglyceride synthesis by adding activated fatty acid moieties 
(i.e., fatty acylCoA) to the glycerol-3-phosphate backbone.  In vitro work has also demonstrated 
an increased TG formation by overexpressing GPAT while mice lacking GPAT are unable to 
accumulate fat mass (65, 66)  However, there is currently little evidence regarding the roles of 
these two key TG synthesis enzymes in adipose tissue of obese adults that remain insulin 
sensitive.  Lastly, fatty acid availability may also be affected by the adipocytes ability to take up 
fatty acids from the systemic circulation. CD36 is a transmembrane protein that is highly 
expressed in adipose tissue, and other tissues, that helps regulate fatty acid uptake, incorporation 
of fatty acids into TG, and lipolysis (67, 68).  Adipose tissue from CD36-null mice exhibit a 
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significant reduction in fatty acid uptake and synthesis of TG and in humans, CD36 protein 
abundance is positively correlated to fatty acid storage rates in subcutaneous adipose tissue (69, 
70).  In addition, obese adults that remain insulin sensitive have a higher abundance of CD36 in 
subcutaneous adipose tissue in combination with lower intrahepatic lipid content compared to 
insulin resistant obese adults (71).  Together, it can be postulated that rates of lipolysis, 
esterification, and fatty acid transport may all play an important role in determining the rate of 
fatty acid mobilization from adipose tissue and subsequently, mediating the degree of skeletal 
muscle insulin resistance. 
 
Adipogenesis 
Adipogenesis is the process of creating new adipocytes and it may also mediate the release 
and storage of fatty acids in obesity.  The expansion of adipose tissue during the development of 
obesity can be accomplished by increasing the size of the existing cells (hypertrophy) and by 
creation of new adipocytes from the resident progenitor cells (hyperplasia).  Weight gain studies 
have demonstrated that initial fat mass expansion may occur primarily through hypertrophy of 
existing adipocytes until a “threshold” in adipocyte hypertrophy and mass are reached; 
hyperplasia then drives further expansion of fat mass (72).  More recent data also suggests that 
the method of adipose tissue expansion may differ amongst the different regions of the body with 
lower body subcutaneous adipose tissue having a much greater expansion through hyperplasia 
versus the abdominal region (73).  At first glance, the manner in which the adipose tissue 
expands its mass may seem trivial since increased fat mass (obesity and overweight) is highly 
related to insulin resistance.  However, hypertrophied or enlarged adipocytes are associated with 
decreased adipogenic capacity, adipose tissue metabolic dysfunction, and insulin resistance (74-
78).  In contrast, obese individuals that remain insulin sensitive have been found to have more, 
smaller fat cells per same volume of fat mass (79).  A fat mass with more hypertrophied fat cells 
may lead to an overall increase in fatty acid mobilization and peripheral insulin resistance.  
Separation of small and large adipocytes from the same subjects demonstrated an increased 
lipolytic rate of large adipocytes when stimulated with catecholamines or inhibited with insulin 
compared with the smaller adipocytes (80).   
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The metabolic status of the adipose tissue is highly related to the inflammatory response, and 
hypertrophied adipocytes have a higher secretion of inflammatory cytokines and immune cell 
chemoattractants, such as MCP-1, that may disrupt insulin signaling (81).  Excess hypertrophy of 
the adipocytes may trigger the increased inflammatory environment seen in insulin resistant 
obesity, and most observed pro-inflammatory adipose tissue macrophages (ATMs) in human 
adipose tissue are observed surrounding hypertrophied adipocytes as “crown-like structures” 
(82).  The ability to create new adipocytes that match nutrient excess through adipogenesis may 
protect against excess lipid mobilization by lessening basal or stimulated lipolysis through 
lessened inflammatory response; although, the lessened inflammatory response may be 
secondary to the increased TG storage capacity if the adipose tissue. 
Adipogenesis is a complex process that is regulated at multiple levels by numerous 
transcription factors, along with multiple extracellular,and intracellular signaling cascades (83).  
The adipogenic process is classically divided into phases: Determination and terminal 
differentiation.  As seen in Figure 2-2, determination involves the commitment of pluripotent 
mesenchymal stem cells (MSCs) to the adipocyte lineage and results in the stem cell becoming a 
“pre-adipocyte”.  Once an MSC is committed to becoming a pre-adipocyte, it unable to 
differentiate into other cells types.  Terminal differentiation occurs when the pre-adipocyte 
begins to develop characteristics of a mature adipocyte- such as the ability to store lipids in TG 
droplets, insulin sensitivity, and the ability to secrete adipocyte specific proteins.  The “master 
regulator” of adipocyte differentiation is peroxisome proliferator-activated receptor-γ (PPARγ), 
which is both necessary and sufficient for adipogenesis (84, 85).  In humans, loss of function 
variants of PPARγ reduce adipogenic capacity and increase the risk for developing diabetes (86).  
In fact, there has yet to be a pro-adipogenic factor discovered that does not function by at least 
activating PPARγ expression to a small degree.  Another major group of regulators in the 
adipogenic processes are the CCAAT-enhancer binding proteins (C/EBPs).  This family of 
proteins directly regulates genes involved in lipid metabolism and similar to PPAR, it is 
considered an important factor in the development of adipose tissue.  Multiple knockout models 
of various members of the protein family (e.g. C/EBPα, C/EBPβ, and C/EBPδ) have 
demonstrated the importance of C/EBPs in adipose tissue development (87, 88), however 
C/EBPs are not able to rescue or promote adipogensis in the absence of PPARγ (89).  Most 
extracellular signaling and environmental cues that seem important for adipogenic processes in 
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vivo converge on the upregulation of PPARγ and C/EBPα expression and activity.  For example, 
insulin, binding of Wnt proteins to β-catenin-dependent and independent pathways, transforming 
growth factor- β (TGFβ), fibroblast growth factor (FGF), bone morphogenetic proteins (BMPs) 
are all implicated in the control of adipogensis through PPARγ and C/EBP pathways.  Insulin, 
FGF, and BMPs, promote formation of adipocytes while Wnt and TGFβ signaling can inhibit 
adipogenesis (90) (83, 91-93).  This simplistic overview of adipogenic processes is a starting 
point for investigating mechanisms that may allow some obese adults to expand adipose tissue 
preferentially through hyperplasia.  Recent work in mice using adipocyte specific, inducible 
fluorescent reporters have shed some light on the creation of new adipocytes during weight gain; 
however, it remains unknown if the response in various fat pads in mice are translatable to the 
response of human adipose tissue in vivo (94).  If it does translate to human adipose tissue, the 
creation of more cells to store excess fat energy will create smaller fat cells and reduce 















FIGURE 2-2: Adipogenesis.  Once adipose stem cells are committed to the adipocyte 
lineage, a variety of extracellular factors can induce differentiation into a mature adipocyte to 
increase the fat storage capacity of the adipose tissue.  Most signaling events in the 
adipogenic process converge on PPARγ, which is essential for the expression of necessary 
lipogenic genes needed for forming a mature adipocyte. 
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ADIPOSE TISSUE METABOLIC FUNCTION EXTENDS BEYOND THE ADIPOCYTE  
Extracellular matrix 
An important component of the adipose tissue structure is the extracellular matrix (ECM) 
that surrounds and encompasses the adipocytes.  The ECM provides a scaffolding-like structure 
to support the structural integrity of the adipocytes as well as participating in many signal 
transduction events important for adipose tissue function (95).  Over the past decade, there has 
been rising interest in the adipose tissue ECM and its role in adipose tissue remodeling and 
metabolic function and it is now recognized that the ECM can potently alter fatty acid storage 
capacity in adipose tissue.  Excess accumulation of ECM components causes fibrosis to occur in 
the adipose tissue of obese individuals and correlates with whole-body insulin resistance (96, 
97).  Using 3T3-L1 cells, Li et al. demonstrated that plating 3T3-L1 cells on high density ECM 
surface can inhibit insulin signaling by increasing activity of pro-inflammatory pathways when 
compared with plating the cells on a lower density ECM (98).  In agreement, elevated adipose 
tissue fibrosis is also highly related to the degree of inflammation in adipose tissue in obesity, 
which can increase insulin resistance (99).  The effects of inflammation in adipose tissue will be 
discussed later in this review.  Collagens, laminins, fibronectin, and proteoglycans all contribute 
to the composition of the ECM, with the role of collagens being the most well-understood thus 
far in relation to obesity and metabolic health.  Special interest has been placed in collagen VI, a 
member of the family of collagen proteins that surrounds adipocytes and anchors adipocytes to 
the basement membrane of the ECM (which contains primarily collagens I, III, and IV).  
Collagen VI is expressed at far greater levels in adipose tissue than other tissues, making it a 
putative candidate for understanding the interaction between adipose tissue structure and 
metabolic function (96).  In humans, collagen VI expression is positively correlated with BMI, 
fat mass, and is upregulated during short-term overfeeding (100).  Conversely, mice that are 
lacking collagen VI are protected from developing insulin resistance on a high fat diet despite 
gaining an equivalent fat mass as wild type mice (96).  The maintenance of insulin sensitivity in 
these collagen VI-null mice was accompanied by larger, more hypertrophied adipocytes per fat 
mass indicating that the lack of collagen VI allowed the adipocytes to expand without the 
constraints seen in the wild type mice and allow for improved fatty acid storage.  It seems that 
collagen VI and fibrosis may play a critical role in mediating the primary function of adipose 
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tissue: storage of excess nutrients as triacylglycerides in lipid droplets.  Obese adults who are 
able to maintain insulin sensitivity may have lower fibrosis in their subcutaneous adipose tissue 
resulting in enhanced lipid storage in the adipocyte, lower mobilization of fatty acids, and lower 
ectopic lipid deposition.  However, it remains unclear if the ECM dictates whole-body metabolic 
health, especially with the close relationship that fibrosis has with inflammation in adipose 
tissue.  Some investigators hypothesize that the immune response may dictate the ECM 
dynamics, so the fibrosis may be secondary to inflammatory signaling.  Moreover, the 
composition and abundance of the ECM is a complex issue, involving proteolytic enzymes that 
control the rate of deposition and degradation of the ECM.  The expression and relative ratios of 
the secreted protein, acidic, and rich in cysteine (SPARC) complex, matrix metalloproteinases 
(MMPs), and tissue inhibitor of metalloproteinases (TIMPs) can all dictate the ECM dynamics 
(101).  While discussing the complex regulation of these very large family of proteins is beyond 
the scope of this review, data from mouse and in vitro models suggests that modulation of these 
proteins may allow for enhanced ability to expand adipocytes under conditions of nutrient 
excess.  For example, Sparc-null mice exhibit an enhanced ability to expand adipose tissue on a 
high fat diet due to less ECM in the adipose tissue (102, 103).  The cumulative data suggests 
ECM plays an important role in dictating the structure, function, and expansion of adipose tissue 
in obesity and may be important for modulating lipid-induced insulin resistance in obesity.  
 
Inflammation and immune response 
It is now well-known that weight gain results in systemic low-grade inflammation and insulin 
resistance (104, 105).  The inflammatory response that occurs as adipose tissue expands with 
weight gain is postulated to be primary mechanism by which obese humans become insulin 
resistant, and accordingly, obese individuals that remain insulin sensitive exhibit lower markers 
of inflammation in their adipose tissue compared with their insulin resistant counterparts (106-
108).  In addition, weight loss is associated with alleviating adipose tissue inflammation and 
reducing the degree of insulin resistance (109).  While growing evidence also suggests a role of 
the adipocytes in the induction of inflammation in obesity, many of the inflammatory 
perturbations are modulated by the resident immune cells that reside within the stromal vascular 
fraction (SVF) of the adipose tissue.  More specifically, adipose tissue macrophages (ATM) are 
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the most dominant leukocyte population in both the lean and obese state, and obesity is 
associated with an increase in the abundance of ATM (110, 111).  Adipose tissue of lean adults 
typically consists of approximately 5-10% macrophages and the proportion can increase to as 
high as 50% in obesity (110).  ATMs are a primary source of pro-inflammatory cytokines, such 
as tumor necrosis factor α (TNF- α) and interleukin-1β (IL-1 β), that can directly or indirectly 
interfere with insulin signaling in adipocytes (112, 113).  Mice lacking gene expression of 
monocyte-chemoattractant protein-1 (MCP-1), which is important for the recruitment of 
macrophages to the adipose tissue during obesity, exhibit lower macrophage accumulation in 
their adipose tissue and remain glucose tolerant despite diet-induced obesity (114).  Conversely, 
mice that overexpress MCP-1 have an elevated infiltration of ATMs in adipose tissue in 
conjunction with increased insulin resistance compared to wild-type mice (114).  However, it is 
not only the amount of infiltration of ATMs that are important for inflammation in adipose 
tissue, but the activation state of the ATMs is also crucial.  Myeloid specific deletion of c-Jun N-
terminal kinase (JNK) or Inhibitor of kB (IkB) kinase (IKK) protected mice from high fat diet-
induced insulin resistance (115-118).  This suggests that inflammation induced insulin resistance 
is a combination of both the recruitment and activation of ATMs in the adipose tissue.  
Macrophages exhibit a vast amount of heterogeneity in function that are affected by the local 
factors in the adipose tissue, which enhance or inhibit the expression of chemokines, cytokines, 
and cell surface receptors that can effect metabolic function.  ATMs exist on a spectrum 
classified by the polarization state as M1 or M2 based on the expression of different anti- or pro-
inflammatory markers.  M1 or “classically activated” macrophages (CD11c+) are marked by 
increased inflammatory cytokine production (e.g. TNF-α, IL-1 β) and generally are considered 
detrimental to human adipocyte insulin sensitivity (119).  With weight gain, there is a shift 
towards a larger population of pro-inflammatory M1 ATM within the immune cell population as 
the fat mass expands,  which is related to insulin resistance (120, 121).  M2 or “alternatively 
activated” macrophages (CD11c-) are characterized by expression and secretion of more anti-
inflammatory cytokines, such as IL-10 and IL-4, and assist with reducing inflammatory 
perturbations and stimulating tissue repair.  The “classically activated” M1 macrophages can 
impair insulin signaling in adipocytes in vitro, while M2 alternatively activated macrophages fail 
to exhibit these effects on the adipocytes (119).  In agreement, ablation of only the CD11c+ 
immune cells (M1) in obese mice eliminates excess markers of inflammation in adipose tissue 
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and normalizes insulin sensitivity without changes in weight (122), which is most likely driven 
by reducing the amount of pro-inflammatory cytokine production by the ATMs.  Tumor necrosis 
factor- α (TNF-α), a cytokine primarily released by M1 ATMs and blocks insulin action through 
serine kinases (JNK, MAPK, IKK) that inhibit IRS-1 phosphorylation by insulin and by altering 
the expression of critical glucose transport proteins (43, 44, 123).  In addition, suppression of 
insulin action impedes the ability of insulin to suppress lipolysis, thus elevating the release of 
fatty acids into the circulation and impairing insulin sensitivity in peripheral tissues.  The 
inflammation-induced increase in lipolysis is a potent stimulus for further inflammatory 
signaling in M1 ATMs (124).  This may provide a mechanistic link by which excess fatty acid 
mobilization from adipocytes may instigate inflammatory processes in the resident immune cells, 
thus propagating further inflammation, insulin resistance, and adipocyte dysfunction.  However, 
it remains unclear whether the inflammatory stress that occurs in expanded fat mass is a cause or 
consequence of elevated fatty acid release from adipocytes in obesity since free fatty acids can 
also induce inflammatory signaling in myeloid cells (125). 
 
Angiogenesis and hypoxia 
The expansion of adipose tissue during prolonged periods of nutrient excess requires the 
proper expansion of the vasculature to provide new cells with the appropriate oxygen and 
nutrients.  The creation of new vasculature, referred to as angiogenesis,  has been implicated as 
one of the primary mediators of adipose tissue metabolic dysfunction and insulin resistance in 
obesity (126).  As adipose tissue expands with overeating, both the hypertrophy of existing 
adipocytes and the creation of new ones require new vasculature to provide appropriate nutrients 
and oxygen, otherwise hypoxic conditions (low partial pressure of oxygen) may occur in the 
tissue.  Diet-induced obesity in mice induces a hypoxic environment in the adipose tissue and, in 
general, obese adults have hypoxic adipose tissue compared to lean persons (127-129).  The 
hypoxic environment may be caused by reduced adipose tissue blood flow (ATBF) and is related 
to the degree of insulin resistance (130).  A common marker used to assess hypoxia, outside of 
the direct measurement of oxygen tension within the tissue, is the measurement of the expression 
and abundance of hypoxia-inducible factor-1α (HIF-1α).  As the name of the protein implies, 
HIF-1α is often considered a master regulator of the hypoxic response (131).  HIF-1α is elevated 
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in the adipose tissue of obese individuals and is negatively correlated with insulin sensitivity 
(132, 133).  The severity of the hypoxic conditions may also mediate inflammatory responses 
and insulin signaling in the adipose tissue (95, 134). In vitro analysis has demonstrated that 
hypoxic conditions can elicit pro-inflammatory responses (e.g. increased expression and 
production of cytokines) in adipocytes and immune cells (128, 135-137).  This coincides with 
observations in human adipose tissue, where markers of hypoxia accompany higher 
inflammation (133).  In addition, the expression of HIF-1α decreases with weight loss, although 
this is paralleled by decreases in many of the inflammatory factors in adipose tissue as well 
(132).  The proposed relationship between fat mass gain, hypoxia, inflammation, and insulin 
resistance is outlined in Figure 3.  One of the genes regulated by the transcription factor HIF-1α 
is vascular endothelial growth factor (VEGF).  The VEGF family of proteins are considered to be 
one of, if not the most important regulator of endothelial cell growth and HIF-1α upregulates 
transcription of VEGF proteins (131).  Ablation of VEGF in mice disrupts the formation of 
adipose tissue during a high fat diet and these animals exhibit high levels of inflammation and 
insulin resistance (138).  Conversely, overexpression of VEGF in the adipose tissue of mice 
increased adipose tissue vascularization and reduced inflammation with weight gain, and 
protected mice from obesity-induced insulin resistance (138).  Although HIF-1α upregulates 
transcription of VEGF, high levels of HIF-1α have been associated with detrimental metabolic 
outcomes in adipose tissue, because HIF-1α also acts as a transcription factor for inflammatory 
pathways, such as NFκB pathways (128, 137).  This is supported by the high level of adipose 
tissue fibrosis, inflammation, and insulin resistance that occurs in mice that overexpress HIF-1α 
in adipose tissue (139).   Conversely, anti-sense mediated deletion or overexpression of a 
dominant negative form of HIF-1α in obese mice exhibit reduced insulin resistance (140, 141).  
Together, this evidence suggests that a hypoxic environment can promote a fibrotic and pro-
inflammatory environment in adipose tissue and propagate insulin resistance.  However, it 
remains unknown whether the hypoxic environment occurs first and promotes adipose tissue 
dysfunction during expansion or if the inability to appropriately expand adipocytes through 







EXERCISE-INDUCED MODIFICATIONS IN ADIPOSE TISSUE STRUCTURE AND 
FUNCTION 
Exercise is an often-prescribed lifestyle intervention to combat the development of insulin 
resistance and disease in obesity (142).  Elevated cardiorespiratory fitness has been reported to 
be associated with reduced cardiovascular risk factors, as well as reduced incidence of CVD, and 
T2DM (143, 144).  Even relatively low physical activity levels have been reported to 
successfully lower incidences of T2DM and CVD (145-147).  Physically active adults typically 
Figure 2-3: Hypoxic conditions induce inflammation and insulin resistance.  As adipose 
tissue expands with weight gain, there is a reduced density of capillarization and a reduced 
adipose tissue blood flow.  This leads to hypoxic conditions within the adipose tissue that can 
increase inflammation, insulin resistance, and fatty acid handling in adipose tissue. 
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have an improved glucose tolerance and insulin sensitivity compared with sedentary individuals, 
which likely contributes to the lower incidence of disease (148, 149).  However, these health 
benefits of exercise may be due largely to the most recent session rather than to adaptations from 
long-term exercise training, per se.  Many studies have distinguished the difference between 
long-term exercise training adaptation and the metabolic benefits of the last session of exercise, 
with most evidence clearly showing that the beneficial effects of exercise on insulin sensitivity 
are transient (~48-72 hours) (150-153).  Furthermore, multiple variables associated with exercise 
such as energy deficit (154), and glycogen depletion (155, 156) can all modulate insulin 
sensitivity and can alter results and interpretation of not carefully controlled (157). 
A large portion of the improvement in insulin sensitivity after a session of exercise is 
attributed to reductions in intramuscular glycogen concentrations, which can prolong the 
elevated glucose uptake that is seen after exercise in rodents and humans (155, 158).  
Importantly, replenishment of glycogen after exercise can quickly reverse the enhanced insulin 
action caused by the exercise bout (155, 156).  Exercise in obese adults may also improve insulin 
sensitivity into the next day due to improvements in muscle fatty acid metabolism.  Schenk et al. 
demonstrated that a 90-minute bout of aerobic exercise increased the expression of key 
esterification enzymes such as DGAT and GPAT and increased the capacity of the skeletal 
muscle to store excess fatty acids as TG (159).  In turn, there were reductions in fatty acid 
intermediates, such as DAG, and lower activation of the serine kinases protein kinase C-θ, c-Jun 
N-terminal kinase (JNK), Inhibitor of kB (IkB) kinase (IKK), and nuclear factor κB (NFκB), 
which can directly and indirectly interfere with the insulin signaling cascade (29).  Exercise can 
be an important lifestyle intervention for reducing lipid-induced insulin resistance in obesity if 
performed regularly, but the exercise training adaptations in skeletal muscle do not appear to 
provide much long-term protection. 
Although much of the focus about the insulin sensitizing effects of exercise has centered on 
changes in skeletal muscle, exercise-induced changes in other tissues and organs may also 
contribute to the metabolic health effects of exercise (160).  Yet surprisingly, very little is known 
about the direct effects of exercise on adipose tissue metabolism.  Only recently has some 
interest been generated in understanding the role of physical activity and exercise on adipose 
tissue due to the recent understanding of adipose tissue’s importance in dictating whole-body 
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health outcomes.  Several studies have reported that exercise has beneficial effects on adipose 
tissue in humans as evidenced by lowered inflammation, fibrosis, and increased adipose tissue 
insulin sensitivity after exercise training, but these studies are confounded by fat mass loss, 
which is known to improve adipose tissue and whole body metabolic outcomes (109, 161).  
However, evidence from some recent animal studies show promising evidence for a beneficial 
effect of exercise, both acute and chronic, on the structure and metabolic function of adipose 
tissue (162-165).  Oliveira et al. exposed obese rats to an acute bout of exercise and observed a 
reduction in inflammatory signaling (p-JNK/JNK, p-IKK/IKK) and expression of pro-
inflammatory cytokines (TNFα, IL-1β, MCP-1) in adipocytes and the resident immune cells 
compared to obese rats that did not complete exercise (162).  These data suggest that adipose 
tissue might be altered by a single session of exercise through reductions in inflammatory 
mechanisms that may translate to improvements in whole-body insulin sensitivity.  A more 
reasonable exercise stimulus of 2 hr of treadmill running was applied to obese mice by 
Macpherson et al. and also showed decreased indices of inflammation of adipose tissue after the 
exercise bout (166).  More specifically, 2 hours after the exercise session, the inguinal adipose 
tissue had decreased expression of CD11c combined with a lower abundance of F4/80 and 
CD11c positive cells.  Insulin induced activation of Aktth308 was also recovered after the exercise 
bout compared with control mice. But more research needs to be done to verify if these results 
are translatable to human physiology and with a more reasonable exercise stimulus (i.e. 45-60 
min moderate aerobic exercise).  
In mice, it was recently demonstrated that short-term exercise training for 11 days, a length 
of time short enough for the mice to not lose body weight, was very effective for beneficially 
altering adipose tissue structure and function (165).  Histological analysis of the adipose tissue 
from the exercised trained mice revealed an increased number smaller adipocytes and increased 
expression of angiogenic markers (e.g. VEGF, PDGF) which may indicate an exercise effect on 
processes controlling adipose tissue expansion (165).  Interestingly, when the investigators 
transplanted adipose tissue from the exercised mice into sedentary mice, glucose tolerance and 
whole-body insulin sensitivity was markedly improved (165).  If exercise training did promote 
structural changes to adipose tissue as noted by Stanford et al., then the beneficial metabolic 
effects of exercise training would be expected to last for many days and weeks after cessation of 
exercise training, but as described above, the insulin sensitizing effects of exercise are often 
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found to be very transient.  One possibility is that the beneficial effects of exercise on adipose 
tissue are only evident during periods of nutrient excess (e.g. weight gain).  The primary role of 
adipose tissue is to store excess energy and exercise may upregulate pathways related to lipid 
storage and adipose tissue expansion and “prime” the adipose tissue for an increased capacity to 
store energy in response to exercise.  Unfortunately, little is known about the role of exercise 
with simultaneous weight gain.  The few studies that have examined the health impact of 
exercise while overeating demonstrated that increased levels of exercise and physical activity 
during overeating may preserve metabolic health (167, 168).  But in these studies, comparisons 
were made by having an overeating groups reduce physical activity levels while overeating, and 
the metabolic impairments in these groups may be a result of reduced physical activity (167, 
168).  Furthermore, these studies were only 7 and 14 days long, and exhibited differences in fat 
gain and caloric balance amongst comparison groups (167, 168).  Multiple studies have been 
produced using mice that have demonstrated beneficial effects of exercise training during weight 
gain (163, 164).  C57BL/6J mice were fed an obesity inducing high fat diet either with or 
without concurrent exercise training on a treadmill for 60 min/day, 5 days/week for 14 weeks 
(163, 164).  Despite no differences in overall body mass between the groups, the exercise trained 
obese mice actually gained more epididymal fat mass than the sedentary obese mice, while 
having vastly smaller liver mass (163, 164).  In addition, the adipose tissue from the exercised 
mice had less infiltration of M1 or CD11c+ macrophages and less T cell infiltration as evidenced 
by histological and mRNA examination.  Furthermore, mice that exercised while gaining weight 
exhibited far less fibrosis of the adipose tissue in conjunction with larger proportion of larger 
sized fat cells.  These studies demonstrate compelling evidence that exercise might enhance the 
lipid storage capacity of adipose tissue by limiting the development of fibrosis and excessive 
inflammation.  However, these studies did not determine if glucose uptake or whole-body insulin 
sensitivity was different between the sedentary and exercise group.  It is not clear whether these 
findings in mice translate to humans.  The compelling evidence that exercise training may alter 
adipose tissue structure and function and lead to improved metabolic health outcome is an 






The high rate of systemic fatty acid mobilization commonly found in obesity is a primary 
determinant in the development of insulin resistance.  The overall working hypothesis of my 
dissertation is that the structure and metabolic function of adipose tissue of obese adults who are 
“protected” from developing insulin resistance differs from the adipose tissue from most other 
obese adults by having greater capacity to expand and store lipid to better match nutrient access 
(See Figure 4).  As a result, the “protected” obese individuals will have a lower release of fatty 
acids from adipose tissue into systemic circulation which allows them to maintain whole-body 
insulin sensitivity. To test this hypothesis, I will examine several factors implicated in the 
determination of fatty acid handling and storage in adipose tissue, such as factors regulating 
lipolysis and esterification, adipogenesis, the extracellular matrix, and immune cells.  
Importantly, exercise is an often-prescribed lifestyle intervention to alleviate insulin resistance, 
yet the impact of exercise on adipose tissue structure and metabolic function is poorly 
understood.  I hypothesize that each session of exercise “primes” adipose tissue for improved 
lipogenic processes such as adipogenesis, angiogenesis, and lipid transport and storage; all of 
which would be highly beneficial for improved health outcomes as people gain weight.  
Together, the projects proposed in this dissertation will identify important factors helping to 
sequester fatty acids in adipose tissue, thereby, attenuating the magnitude of systemic fatty acid 








Figure 2-4: How the adipose tissue expands in obesity may dictate whole-body insulin 
sensitivity.  Weight gain and increased fat mass are associated with whole-body insulin 
resistance due in part to the metabolic responses in adipose tissue.  Increased immune cell 
infiltration and inflammation, increased fibrosis, decreased capillary density, and 
hypertrophied adipocytes have all been reported to be associated with excess fatty acid release 
and subsequent whole-body resistance.  Obese adults that remain insulin sensitive may have 
favorable adipose tissue responses to weight gain, such as smaller fat cells per fat mass, 
reduced immune cell infiltration and inflammation, and higher capillary density when 
compared to insulin resistant obese adults, which results in lower fatty acid release and 
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Relatively low endogenous fatty acid mobilization and uptake helps preserve insulin 
sensitivity in obese women 
 
Abstract 
Although obesity is commonly linked with metabolic disease risk, there are still some obese 
adults who remain relatively healthy. The primary aim of this study was to determine if 
alterations in fatty acid metabolism may underlie differences in insulin sensitivity (Si) among a 
seemingly homogeneous cohort of obese women. We measured insulin sensitivity (FSIVGTT), 
basal fatty acid rate of disappearance from plasma (Rd), whole-body fat oxidation, and 
performed a muscle biopsy in 21 obese women. We found Si to be inversely related to fatty acid 
Rd (R2=0.21; P=0.04).  We then divided our subjects into tertiles based on their Si, and compared 
the subset of subjects with the lowest Si (LOW-Si; Si ≤ 2.1 (mU/L)-1·min-1; n=7) with the subset 
of our subjects with the highest Si, who exhibited relatively normal insulin sensitivity (NORM-
Si; Si ≥ 3.4 (mU/L)-1·min-1; n=8). Despite nearly identical physical characteristics in LOW-Si vs 
NORM-Si (BMI: 34±2 vs 34±1 kg/m2; % body fat: 48±1% vs 47±1%; waist circumference: 
104±2 vs 104±2 cm; VO2peak: 2.2±0.2 vs 2.3±0.1 L/min), fatty acid Rd was nearly 30% lower in 
NORM-Si (P=0.02).  Activation of inflammatory pathways known to impair insulin action in 
skeletal muscle was also lower in NORM-Si vs. LOW-Si (i.e. lower phosphorylated JNK, higher 
IκBα abundance).  In contrast, LOW-Si and NORM-Si exhibited no differences in systemic 
markers of inflammation (i.e. TNFα, IL-6, MCP-1), basal whole-body fat oxidation, and 
intramyocellular lipid concentrations.  Our findings suggest that obese adults who maintain 
relatively low rates of endogenous fatty acid mobilization and uptake may be somewhat 











Obesity is often associated with metabolic complications, such as insulin resistance, 
which is a major contributor to the development of several chronic diseases, including type 2 
diabetes (1).  Despite the common link between obesity and disease risk, there are still many 
obese adults who appear to be somewhat “protected” against the development of many chronic 
health issues.  In fact, based on data collected as part of the National Health and Nutrition 
Examination Survey (NHANES) it has been reported that over 30% of obese adults are classified 
as “metabolically healthy” (2).  However, it is still unclear why some obese adults are more 
prone to develop metabolic complications, like insulin resistance, while others are not, even 
when they are very similar in terms of the magnitude and distribution of their adiposity. 
Abdominally obese individuals typically have elevated fatty acid availability compared to 
their lean counterparts (3), and this excessive systemic fatty acid availability and uptake have 
been identified as key factors underlying insulin resistance in obesity.  Lipid infusions used to 
elevate systemic fatty acid availability in healthy, lean participants have been found to 
profoundly suppress their insulin sensitivity (4, 5). Furthermore, acute and chronic 
administration of the lipolytic inhibitor acipimox in obese adults decreased fatty acid availability 
and enhanced insulin sensitivity (6-8).  The high rates of fatty acid availability and uptake into 
insulin responsive tissues like skeletal muscle have been found to induce insulin resistance in 
part via the intracellular accumulation of lipid intermediates, such as diacylglycerides, 
ceramides, and fatty acyl-CoA (9, 10).  In turn, accumulation of these intermediates is linked 
with increased activation of pro-inflammatory pathways (e.g.; c-jun N-terminal kinase (JNK), 
and inhibitor of kB/nuclear factor-kB (IkB/NF-kB)) that disrupt the insulin signaling cascade 
(11-14).  Together, these findings highlight the progression of elevated systemic fatty acid 
availability and subsequent inflammatory pathway activation toward the development of insulin 
resistance.  Importantly, while lipolytic rate and fatty acid availability are typically elevated in 
obese compared with lean adults (3), there is still considerable variability among the obese 
population (15).  However, it remains unclear if the magnitude of endogenous fatty acid flux 
contributes to differences in the severity of insulin resistance in obesity. 
The overall objective of this study was to identify factors that may help explain 
differences in insulin resistance among a seemingly homogeneous cohort of obese sedentary 
women.   More specifically, we sought to determine whether the magnitude of fatty acid uptake 
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and markers of inflammatory pathway activation in skeletal muscle were related with the degree 
of insulin resistance in obese adults.  We hypothesized that obese adults with the lowest rate of 
fatty acid flux would exhibit relatively low pro-inflammatory pathway activation in skeletal 






Twenty-one sedentary, obese adults (body mass index (BMI): 30-40 kg/m2; waist circumference 
>100cm) were recruited to participate in the study.  All women were premenopausal and 
considered to be in good health after a medical examination. The medical evaluation included a 
history questionnaire, physical examination, and a resting 12-lead electrocardiogram.  The 
participants were not taking regular medications, except for those women who were taking 
contraceptive medication. All subjects were nonsmokers, weight stable (±2 kg) for 6 months and 
had not participated in regular exercise for at least 6 months before participating in the study. 
Participants with coronary heart disease, type 2 diabetes, hypertension or clinically significant 
hypertriglyceridemia (plasma triacylglycerol concentration >150 mg/dl) were excluded.  Written, 
informed consent was obtained from all subjects before initiating participation. All procedures of 
this study were approved by the University of Michigan Institutional Review Board. 
 
Preliminary testing 
Body composition was determined using dual X-ray absorptiometry (Lunar DPX DEXA 
Scanner, Madison, WI, USA). Subjects performed an incremental peak oxygen uptake test 
(VO2peak) on a stationary bicycle ergometer to assess aerobic fitness. The protocol consisted of 




The trial was performed during the first 2 weeks of the female participants’ menstrual cycle. 
Participants were admitted to the Michigan Clinical Research Unit (MCRU) at the University of 
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Michigan hospital at 1800 h and stayed overnight. A standardized meal was provided at 2000h 
and the participants remained fasted after the meal until completion of the trial the next day.  At 
0700 h the next morning, a skeletal muscle biopsy was obtained from the vastus lateralis. We 
separated any adipose and connective tissue from the muscle sample, rinsed it clean with saline, 
blotted it dry, and froze it in liquid nitrogen and store at − 80 °C until later analysis. Intravenous 
catheters were placed in a hand vein for blood sampling and in a forearm vein of the opposite 
arm for infusion of the stable isotope tracer, [13C]-palmitate (Cambridge Isotope Laboratories, 
Andover, MA, USA). A blood sample was obtained before the start of the tracer infusion to 
assess background [13C]-palmitate enrichment and to measure baseline concentrations of plasma 
pro-inflammatory markers (TNF-a, interleukin-6 (IL-6) and MCP-1). At 0800 h, a constant 
infusion of [13C] palmitate (0.04 µmol kg− 1 min−1) bound to human albumin (Baxter, 
Deerfield, IL, USA) began, and four arterialized blood samples were collected in 5-min intervals 
from a heated hand vein at minutes 45, 50, 55 and 60 for determination of FA Ra. Resting 
whole-body fat oxidation was calculated from the rates of oxygen consumption (VO2) and 
carbon dioxide production (VCO2) using a metabolic cart (Delta Trac, Sensor Medics, Yorba 
Linda, CA, USA). After all of the fatty acid metabolism measurements, a frequently sampled 
intravenous glucose tolerance test (FSIVGTT) was conducted to assess insulin sensitivity (Si) 
using the minimal model technique.   
 
Analytical Procedures 
Plasma fatty acid kinetics 
The tracer-to-tracee ratio for plasma palmitate was determined by gas chromatography–mass 
spectrometry with an MSD 5973 system (Agilent Technologies, Wilmington, DE, USA) with 
capillary column as previously described (16). Plasma palmitate concentration was measured by 
the internal standard method using gas chromatography/flame ionization detection.  Proteins 
were precipitated from plasma samples with acetone, and hexane will be used to extract plasma 
lipids. For palmitate analysis, fatty acids in the organic phase of the extraction sample were 
converted to their methyl esters with iodomethane and isolated by using solid phase extraction 
cartridges (Supelclean LC-Si Silica gel SPE tubes; Sigma Inc). Electron impact ionization was 





Plasma glucose, fatty acid, and insulin concentrations 
Plasma glucose (Thermo Scientific, Waltham, MA, USA) and fatty acid (Wako Chemicals USA, 
Richmond, VA, USA) concentrations were measured using commercially available colorimetric 
assay kits. Plasma insulin concentration was measured by radioimmunoassay (Linco Research 
Inc., St Louis, MO, USA). 
 
Intramyocellular triacylglycerol concentration 
Frozen muscle samples (~20 mg) were lyophilized at –60°C for 48h, and aliquots will be 
weighed to the nearest 0.1 mg. IMTG was measured from the liberation of free glycerol (17). 
Triacylglycerol was extracted from the dried muscle sample using 2:1 chloroform:methanol and 
saponified in 4% ethanolic KOH. Free glycerol concentration in these samples was determined 
fluorometrically. 
 
Muscle tissue lysate preparation 
Frozen muscle samples were weighed and transferred into prechilled microfuge tubes containing 
1 ml ice-cold lysis buffer and a steel ball bearing. Tissue samples were then be homogenized in 
the microfuge tubes for 1 min using a Qiagen TissueLyser II (Qiagen, Hilden, Germany). The 
lysis buffer contained T-PER Tissue Protein Extraction Reagent (#78510, Fisher Scientific, 
Waltham, MA, USA), 1mM EDTA, 1mM EGTA, 2.5mM sodium pyrophosphate, 1mM sodium 
orthovanadate, 1mM β-glycerophosphate, 1 µgml − 1 leupeptin and 1mM phenylmethylsulfonyl 
fluoride. This lysis buffer recipe has been used successfully by Dr. Greg Cartee’s laboratory for 
use with muscle tissue multiplex analysis.  To remove insoluble material, the homogenates were 
transferred to new microfuge tubes and rotated for 1 hour at 4 °C and then centrifuged at 15,000 
g for 15 min at 4 °C. Protein concentration were determined using the bicinchoninic acid method 
(Thermo Scientific, Rockford, IL, USA). 
 
Multiplex analysis 
Plasma cytokines and skeletal muscle proteins associated with inflammation were quantified 
using a commercially available Multiplex bead assay as per manufacturer recommendations 
(Luminex L200, Luminex, Austin, TX, USA). Plasma was assayed for IL-6, TNF-α and MCP-1 
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(#HCVD3-67CK, Milliplex MAP Kit, Millipore, Billerica, MA, USA). Prepared tissue lysates 
were analyzed for total protein abundance of JNK and IkBα and separately analyzed for the total 
phosphorylation of JNKThr185/Tyr185 (#48-602, Milliplex MAP Kit, Millipore). 
 
Subject stratification based on degree of insulin resistance 
After examining the relationship of FA Ra and insulin resistance across the entire cohort, we 
divided the group into tertiles based on their magnitude of insulin sensitivity.  Obese adults that 
maintained an insulin sensitivity similar to lean individuals were designated as “NORM-Si” 
while those that exhibit the lowest one-third of insulin sensitivity were designated as “LOW-Si”.  
Importantly, we ensured the groups exhibited homogenous physical characteristics (e.g. body 
mass, fat mass, cardiorespiratory fitness, etc.) in order to eliminate variables known to affect 




Whole-body fat (i.e., triacyglycerol) oxidation (g·min− 1) was calculated from VO2 and VCO2 
measurements using the equations of Frayn (18). Whole-body fatty acid oxidation was calculated 
by dividing triacylglycerol oxidation by an estimated molecular weight of triacylglycerol (860 
g·mol− 1) and multiplying by 3. 
 
Fatty acid mobilization 
Palmitate rate of appearance (Ra) into plasma was calculated using the Steele equation for 
steady-state conditions (19).  Fatty acid Ra was calculated by dividing palmitate Ra by the ratio 
of plasma palmitate to total plasma fatty acid concentration. 
 
Insulin sensitivity index (Si) 
The insulin sensitivity index (Si) was calculated from least squares fitting of the insulin and 
glucose concentration curves from the frequently sampled intravenous glucose tolerance test 
(FSIVGTT) using the Minimal Model Millenium (version 6.02; MinMod Inc., Pasadena, CA, 






Simple linear regression was used to assess significance in the relationship between Si and fatty 
acid Ra among all subjects (n=21).  Unpaired Student’s t-tests was used to test for significant 
between-group (NORM-Si vs LOW-Si) differences in all outcome variables.  Simple linear 
regression was also used to test for significant relationship between FA Ra and markers of 
inflammation in the circulation (e.g., IL-6, TNF-a, MCP-1) and in skeletal muscle (e.g., IκBα, 





Insulin sensitivity index and cohort stratification 
As anticipated, the subject pool was largely homogeneous in terms of BMI, adiposity, waist 
circumference, and cardiorespiratory fitness, however, Si  varied widely among the 21 subjects 
(Figure 3-1), ranging from 4.8 to 0.8 (mU/L)-1/min.  As noted in Figure 3-1A, subjects with an Si 
in the lowest one-third of our overall subject pool (≤ 2.1 (mU/L)-1/min) were grouped into our 
low insulin sensitive cohort (“LOW-Si”; n=7) and those in the highest one-third (≥ 3.4 (mU/L)-
1/min) were grouped into our normal insulin sensitivity cohort (“NORM-Si”; n=8).  We used the 
term “normal” to define the Si of our most insulin sensitive subjects in this study because these 
obese subjects had a similar Si as we previously reported in healthy lean adults (13)(20), and as 
such we identified this cohort as exhibiting “normal” insulin sensitivity.  As designed, the 
difference in Si between NORM- Si and LOW- Si was significant (Figure 3-1B; P<0.000001), 
but importantly, these groups were very well matched for BMI, adiposity, waist circumference, 
and cardiorespiratory fitness (Table 3-1). In order to compare groups with distinct differences in 
insulin sensitivity, our primary comparisons did not include subjects with Si values between 2.1 
and 3.4 (mU/L)-1/min (grey bars in Figure 3-1).  The subjects with intermediate Si were included 





In conjunction with the higher insulin sensitivity in NORM- Si compared with LOW- Si, FA 
uptake was nearly 30% lower in NORM-Si vs. LOW-Si  (Figure 3-2; P<0.02).  Despite this lower 
rate of FA uptake in NORM-Si vs. LOW-Si, resting whole-body fatty acid oxidation was not 
different between groups (3.7 ± 0.2 vs 3.5 ± 0.2 µmol/kg/min, respectively). Interestingly, FA 
uptake was reasonably well matched to the rate of fatty acid oxidation in the NORM-Si cohort 
(3.7 ± 0.2 vs. 3.8±0.5 µmol/kg/min, respectively), but in our LOW-Si cohort the rate of FA 
uptake exceeded fatty acid oxidation by nearly 50% (5.2±0.4 vs. 3.5 ± 0.2 µmol/kg/min, 
respectively).  However, this disparity between fatty acid uptake and fat oxidation in LOW-Si did 
not translate to a measureable increase in IMTG accumulation, which was similar between 
groups (63.7 ± 6.7 vs. 68.3 ± 12.7 vs. µmol/g dry weight for NORM- Si and LOW- Si, 
respectively). 
 
Markers of inflammation 
Within skeletal muscle, JNK phosphorylation (p-JNK) was significantly lower in NORM-Si  
compared with LOW-Si  (Figure 3-3A), suggestive of an attenuated inflammatory pathway 
activation in muscle from our NORM-Si subjects.  Interestingly, a lower total JNK protein 
abundance in NORM-Si vs, LOW-Si (101±10 vs. 149±20 arbitrary units (AU), respectively; 
p≤0.05) may underlie much of the difference in p-JNK between the groups.  We also found a 
greater protein abundance in IκB-α in muscle from NORM-Si compared with LOW-Si (Figure 
3B), but this difference between groups did not quite reach statistical significance (p=0.067). 
Because IκB-α suppresses activation of the IKK-NFκB inflammatory pathway (21), the trend we 
observed for a greater abundance of IκB-α in muscle from NORM-Si vs LOW-Si subjects is 
indicative of reduced inflammatory/stress in NORM-Si. In contrast to the differences in markers 
of inflammation we found in skeletal muscle of NORM-Si vs LOW-Si, there were no significant 
differences in fasting plasma concentrations of IL-6 (15.0 ± 8.4 vs. 23.8 ± 10.0 pg/ml), TNF-α 





Relationships between insulin sensitivity, fatty acid uptake, and inflammatory markers 
Using our entire subject population in this study (n=21), we found a significant inverse 
correlation between FA uptake and Si, (Figure 3-4A; R2=0.21; p = 0.04), further supporting the 
notion that those with relatively low FA uptake were the most insulin sensitive.  Similarly, we 
found a significant positive relationship between abundance of IκB-α within the skeletal muscle 
and Si (Figure 3-4B; R2=0.22; p=0.035), as well as a trend for an inverse relationship between 
pro-inflammatory p-JNK and Si (Figure 3-4C; R² = 0.18; p= 0.06), suggesting that preservation 
of lower inflammatory/stress in skeletal muscle is related to a greater insulin sensitivity. 
 
Discussion 
Clearly there are some obese adults who are generally in good health, while many others 
have serious metabolic complications (2). We found that just over one-third of our obese cohort 
exhibited “normal” insulin sensitivity, which matched very well with epidemiological evidence 
using data collected from the National Health and Nutrition Examination Survey (NHANES) (2).  
However, it is not clear why some obese adults are prone to develop insulin resistance (as well as 
other cardio-metabolic complications), while others appear to remain somewhat “protected”.  In 
our subjects, differences in cardiorespiratory fitness, resting fat oxidation, or skeletal muscle 
triglyceride accumulation could not explain the disparity in insulin resistance.  Instead, our main 
findings suggest that a relatively low basal rate of fatty acid uptake may be a key contributor 
protecting against insulin resistance in obese adults. 
An overabundance of fatty acids have long been known to induce insulin resistance (4, 
5).  Excessive fatty acid uptake into insulin responsive tissues like skeletal muscle is thought to 
induce insulin resistance in part via the intracellular accumulation of lipid intermediates, such as 
diacylglycerides, ceramides, and fatty acyl-CoA (9, 10).  Theoretically, high rates of fatty acid 
oxidation may help compensate for high rates of fatty acid uptake, thereby attenuating the 
accumulation of lipid intermediates, which may help protect against the development of insulin 
resistance (22).  However, the impact that normal variation in resting fatty acid oxidation may 
have on the development of insulin resistance is debated (23, 24).  In our study, rates of fatty 
acid oxidation were identical in NORM-Si and LOW-Si, so differences in the oxidative disposal 
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of fatty acids were not contributing to the differences in insulin sensitivity observed between 
these groups.  In contrast, a 50% greater rate of fatty acid uptake in the LOW-Si group was 
responsible for creating a large mismatch between the rates of fatty acid uptake and oxidation in 
this group.  Although we did not measure the muscle accumulation of diacylglycerol, ceramide, 
or fatty acyl-CoA in this study (due to limitations in the amount of skeletal muscle tissue 
available for analysis), it is plausible that a disparity between fatty acid uptake and oxidation of 
this magnitude may have led to an accumulation of these lipid intermediates.  In turn, the 
accumulation of these lipids within the muscle cell can increase the activation of inflammatory 
pathways, which may contribute to the impairment in insulin action (25, 26).  
It has become evident that increased inflammatory pathway activation in skeletal muscle 
is an important link between altered fatty acid metabolism and impaired insulin signaling (25).  
For example, incubating skeletal muscle cells in media containing a high concentration of fatty 
acids is known to activate cellular inflammatory factors, such as Inhibitor of nuclear factor kappa 
B kinase (IKK) and c-jun n-terminal kinase (JNK), which mediate the suppression in insulin-
stimulated glucose uptake (14, 27, 28).  More clinically relevant, the high rates of fatty acid 
mobilization and uptake commonly found in obesity (3) is often accompanied by an elevated 
activation of JNK (11, 29) and/or IKK (27, 29) in skeletal muscle.  Importantly, 
pharmacologically induced suppression in fatty acid availability in human subjects was found to 
suppress the activation of inflammatory pathways in skeletal muscle, and improve insulin action 
(6-8). Furthermore, previous work in our laboratory demonstrated that the improvement in 
insulin sensitivity found after weight loss was largely attributed to the weight loss-induced 
reduction in fatty acid availability, with an accompanying decline in the activation of the 
inflammatory JNK and IKK-NFκB pathways (30).  Our observation that the relatively low rate 
of fatty acid uptake in our NORM-Si subjects was accompanied by lower p-JNK and a higher 
IkBa abundance highlights the importance of the magnitude of fatty acid uptake as a key 
mediator of inflammation and insulin sensitivity within skeletal muscle. 
When examining health disparities among obese adults, there is considerable emphasis on 
the role that differences in anatomical distribution of body fat (i.e., subcutaneous vs. visceral) 
may play on determining metabolic health in obesity.  Abdominal obesity is most commonly 
linked with insulin resistance (31, 32), as well as other cardiovascular disease risk factors (33, 
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34).  More specifically, accumulation of fat in the visceral region is typically identified as being 
an especially potent contributor to the development of metabolic disorders (35-37).  We 
attempted to control for abdominal obesity in our study population by matching waist 
circumference between our NORM-Si  and LOW-Si  groups.  It has been demonstrated that waist 
circumference can provide a reasonably accurate surrogate measure for visceral adiposity when 
compared to more precise measurements (e.g. MRI) (33).  However, because we did not 
definitively assess visceral fat mass, we cannot rule out the possibility that potential differences 
in visceral adiposity may help explain some of the observed difference in insulin sensitivity 
among our subjects.  Some suggest that visceral adiposity contributes to insulin resistance as a 
consequence of the relatively high lipolytic rate measured in visceral compared with 
subcutaneous adipocytes (38, 39), which in turn may lead to excessive FFA availability known to 
impair insulin action.  Yet, while high lipolytic rates in visceral vs. subcutaneous adipocytes are 
commonly found when measured in vitro, in vivo measurements indicate that about 85% of 
systemic fatty acids are derived from subcutaneous rather than visceral adipose tissue (40).  
Similarly, only about 20% of fatty acids delivered to the liver were found to be derived from 
visceral adipose tissue (40).  Therefore, the vast majority of fatty acids delivered to, and taken up 
by skeletal muscle and liver (i.e., the majority of fatty acids that may enhance 
inflammatory/stress and insulin resistance in these tissues) likely originate from subcutaneous, 
rather than visceral adipose tissue.   
The rate of fatty acid mobilization from subcutaneous adipose tissue has recently been 
reported to vary widely among a cohort of obese adults (15), and our findings support this 
notion.   The rate of fatty acid release from adipose tissue is determined in large part by the rate 
of lipolysis, which liberates fatty acids from triglycerides.  Therefore, a relatively low lipolytic 
rate within adipose tissue would suppress the mobilization of fatty acids into the systemic 
circulation, which may lower the risk for developing insulin resistance.  The abundance and 
activation of adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) largely 
dictate the rate of lipolysis within adipose tissue (41, 42). Lipolytic rate has recently been 
positively associated with insulin resistance in humans (43).  Furthermore, the same authors also 
showed that inhibition of HSL and the subsequent reduction in fatty acid mobilization from 
adipose tissue in mice resulted in improved glucose tolerance without changes in body mass 
(43). Importantly, the rate of triglyceride synthesis (i.e., fatty acid esterification) can also 
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modulate the rate fatty acid release, and it has recently been reported that obese individuals with 
a relatively high capacity for triglyceride synthesis in subcutaneous adipose tissue were largely 
protected from insulin resistance (15).  Triglyceride synthesis within adipose tissue is regulated 
by a series of enzymes (i.e., glycerol phosphate acyltransferase (GPAT), acylglycerolphosphate 
acyltransferase (AGPAT), phosphatidic acid phosphatase (PAP), and diacylglycerol 
acyltransferase (DGAT)) that catalyze the esterification of three fatty acyl-CoA moieties to a 
glycerol backbone. Future studies designed to further examine the abundance and activity of key 
factors that regulate fatty acid release and triglyceride synthesis in adipose tissue will help 
identify potential mechanisms mediating the differences in fatty acid mobilization in obesity 
independent of adiposity. 
It is important to acknowledge that we measured fatty acid mobilization in the post-
absorptive state, and obviously insulin resistance was assessed during the subsequent IVGTT.  
Because insulin potently suppresses lipolysis (44), individual variability in the magnitude of the 
insulin-mediated suppression of fatty acid mobilization may have also contributed to the 
variability in insulin resistance among our subjects.  In fact, Magkos, et al., (45) recently 
reported that the magnitude of the insulin-induced suppression in fatty acid mobilization was 
significantly correlated with insulin-mediated glucose uptake.  Interestingly, despite also 
demonstrating a significant relationship between post-absorptive fatty acid availability and 
insulin resistance (similar to our present findings), the authors challenged the notion that fatty 
acid mobilization in the post-absorptive state was an important contributor to the development of 
insulin resistance (45).  We agree that if fatty acid availability remains relatively high despite 
insulin exposure (e.g., after a meal, during an IVGTT, or hyperinsulinemic clamp) – this 
certainly could contribute to the development of insulin resistance.  However, even among their 
most insulin resistant subjects, Magkos, et al (45) found insulin suppressed fatty acid 
mobilization at least 35% below post-absorptive levels, and the absolute fatty acid availability 
was relatively low in response to insulin in all subjects.  Moreover, if the accumulation of lipid 
intermediates within the muscle cell does indeed play an important role in the development of 
insulin resistance (9, 10), these intracellular lipids likely accumulate in large part in the post-
absorptive state, when fatty acid availability is highest.  Therefore, we contend that the exposure 
to high availability of fatty acids that is often found in the post-absorptive state of many obese 
adults, can have a potent impact on insulin resistance.  
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Interestingly, we did not find any differences in plasma cytokines known to be involved 
with systemic inflammation between the NORM-Si  and LOW-Si  groups.  There were no 
significant correlations of the measured cytokines among the entire cohort as well (data not 
shown).  The chronic low grade inflammation observed in obesity is partly attributed to elevated 
systemically circulating inflammatory cytokines such as Tumor Necrosis Factor (TNF-α) and 
Interleukin 6 (IL-6) (46, 47).  We can possibly attribute these results to a smaller sample size and 
the inherent variability typically observed in these circulating cytokines.  Alternatively, it may be 
indicative that the inflammatory response is primarily mediated within the peripheral tissues as 
opposed to the systemically circulating cytokines. 
In conclusion, our findings indicate that variability in systemic fatty acid availability and 
tissue uptake are key mediators of the observed differences in insulin resistance among a 
seemingly homogenous cohort of obese women.  More specifically, obese subjects who had a 
relatively low rate of fatty acid uptake appear to be somewhat "protected" against the 
development of insulin resistance.  This lower rate of fatty acid uptake was accompanied by a 
lower activation of markers for inflammatory pathways within the skeletal muscle, and 
consequently, a higher insulin sensitivity when compared with our subjects with a relatively high 
rate of fatty acid uptake.  Importantly, the observed variability in insulin resistance among our 
obese subjects could not be attributed to differences in basal fat oxidation, common markers of 
systemic inflammation (e.g., IL-6, TNF-α, MCP-1), skeletal muscle triglyceride accumulation, or 
cardiorespiratory fitness.  It is likely that differences in the regulation of fatty acid storage and 
release from adipose tissue mediates a large portion of this observed variability in fatty acid 
availability and uptake.  Therefore, it is now very important to identify the factors underlying the 
relatively low fatty acid availability and uptake among obese individuals who are not insulin 
resistant (and/or factors underlying the high fatty acid availability among those who are) in order 
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subjects NORM-Si LOW-Si 
Age (y) 30 ± 1 32 ± 2 29 ± 3 
Body Mass (kg) 93 ± 2 92 ± 2 91 ± 5 
BMI (kg/m2) 34 ± 1 34 ± 1 34 ± 2 
Waist circumference (cm) 104 ± 1 104 ± 2 104 ± 2 
Fat mass (kg) 44 ± 2 44 ± 1 44 ± 4 
Fat free mass (kg) 49 ± 1 49 ± 1 48 ± 2 
Body fat (%) 48 ± 1 47 ± 1 48 ± 1 
VO2peak (ml/kg/min) 24 ± 1 25 ± 1 23 ± 1 
Data presented as Mean ± SE. 

















Figure 3-1: Insulin sensitivity. (a) Insulin sensitivity index (Si) measured in the morning after an 
overnight fast in all subjects (n= 21). Subjects were ordered from highest to lowest Si, and 
stratified into tertiles to identify a low insulin sensitivity cohort (LOW-Si; Si⩽ 2.1 (mU/l) − 1 
min− 1; n=7) and a normal insulin sensitivity cohort (NORM-Si; Si⩾3.4 (mU/l) − 1 min− 1). (b) 
Mean Si in NORM-Si and LOW-Si cohorts. *P<0.000001 vs NORM-Si. Values presented as 





Figure 3-2: Fatty acid uptake. Fatty acid rate of disappearance from plasma (Rd) in NORM-Si 
and LOW-Si cohorts, measured in the morning after an overnight fast. *P<0.05 vs NORM-Si. 



















Figure 3-3: Insulin-induced suppression of plasma fatty acid concentration. Plasma fatty acid 
concentration during the 3 h IVGTT in LOW-Si (white square □) and NORM-Si (black square 
■).Values presented as MEAN ± SE. *Significant difference in area under the curve between 




















Figure 3-4: Markers of inflammation. (a) Total protein abundance of phosphorylated c-Jun N-
terminal kinase (p-JNK). (b) Total protein abundance of inhibitor of NF-κBα (IκB-α). *P<0.05 





















Figure 3-5: Correlational analyses for insulin sensitivity with fatty acid uptake and inflammatory 
markers in skeletal muscle. (a) Correlation between insulin sensitivity index (Si) and fatty acid 
uptake. (b) Correlation between Si and IκB-α abundance. (c) Correlation between Si and p-JNK 
abundance. All correlational analyses were performed using the entire subject cohort (n =21) 
(LOW-Si (n=7; white square □), NORM-Si (n =8; black square ■) and participants who did not 
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Factors regulating subcutaneous adipose tissue storage, fibrosis, and inflammation may 
underlie low systemic rates of fatty acid mobilization in insulin sensitive obese adults. 
 
Abstract 
Although the rate of fatty acid release from adipose tissue into the systemic circulation is very high 
in most obese adults, some obese adults maintain relatively low rates of fatty acid release, which 
helps protect them against the development of systemic insulin resistance.  The primary aim of 
this study was to identify factors in adipose tissue that may underlie low vs. high rates of fatty acid 
mobilization in a relatively homogeneous cohort of obese adults. We measured systemic fatty acid 
rate of appearance (FA Ra) via 13C-palmitate isotope dilution, and we obtained subcutaneous 
abdominal adipose tissue samples from 30 obese adults (BMI: 38±1 kg/m2, age: 30±2 yr) after an 
overnight fast.  We then measured insulin sensitivity using a hyperinsulinemic-euglycemic clamp. 
Confirming our previous work, insulin sensitivity was inversely proportional to FA Ra (R2=0.50; 
p<0.001).  Immunoblot analysis of subcutaneous adipose tissue samples revealed that, compared 
with obese adults with high FA Ra, those with low FA Ra had lower markers of lipase activation 
and higher abundance of glycerol-3-phosphate acyltransferase (GPAT), which is a primary 
enzyme for fatty acid esterification. Microarray and pathway analysis provided evidence of lower 
fibrosis and lower SAPK/JNK pathway activation in obese adults with low FA Ra compared to 
those with high FA Ra. Our findings suggest that alterations in factors regulating triglyceride 
storage in adipose tissue, along with lower fibrosis and inflammatory pathway activation, may 
underlie maintenance of a relatively low FA Ra in obesity, which may help protect against the 




Obesity is associated with insulin resistance, which is central to the development of many 
cardio-metabolic diseases.  However, up to one-third of obese adults remain metabolically healthy 
(i.e., not insulin resistant) (1); these “insulin sensitive” obese adults have fewer metabolic health 
complications, and their mortality rates are similar to lean, healthy individuals (2, 3).  While it 
remains unclear why some obese adults remain insulin sensitive, mounting evidence suggests 
adipose tissue plays an important role. 
Much of the insulin resistance observed in obesity is a consequence of excessive release of 
fatty acids into systemic circulation (fatty acid mobilization [FA Ra]) and the resultant ectopic 
lipid deposition that disrupts insulin signaling in peripheral tissues.  In fact, several studies report 
profound insulin resistance in healthy, lean subjects after short-term lipid and heparin infusion to 
mimic the high FA Ra found in obesity (4, 5).  Conversely, drugs that lower systemic fatty acid 
availability in obese adults can reverse insulin resistance (6, 7).  Our lab and others have 
demonstrated that the degree of FA Ra dictates the degree of insulin resistance in obesity and that 
obese adults who maintain a relatively low basal FA Ra remain insulin sensitive (8, 9). However, 
while it is clear that the rate of FA Ra from adipose tissue can greatly impact insulin resistance, 
little is known about factors that may help sequester excess fatty acids in adipose tissue, and 
thereby limit ectopic lipid deposition.   
The accumulation of visceral adipose tissue is often linked with the severity of cardio-
metabolic disease risk (10); however, the excess accumulation of visceral fat most likely results 
from the subcutaneous adipose tissue’s inability to effectively store excess nutrients. Nielsen et al. 
(11) demonstrated that approximately 90% of circulating fatty acids are derived from subcutaneous 
adipose tissue, with nearly 70% of these fatty acids coming from abdominal subcutaneous adipose 
tissue.  Moreover, despite the anatomical proximity of visceral adipose tissue to the liver, the vast 
majority of fatty acids in the hepatic circulation are also derived from abdominal subcutaneous 
adipose tissue (11).  Human studies using deuterated water to track long-term turnover and storage 
of triacylglycerol (TG) found that TG synthesis and storage are impaired in the subcutaneous 
adipose tissue of insulin-resistant obese individuals compared with obese adults who maintain 
normal insulin sensitivity (12).  These data demonstrate the importance of subcutaneous adipose 




The factors responsible for differences in FA Ra in obesity are not clear, and although the 
enzymes regulating TG hydrolysis and esterification are well described, the regulation of fatty acid 
release from adipose tissue is far more complex.  Various adipose tissue factors have been 
postulated to be important mediators of adipose tissue function, including cell size (13), lipid 
storage capacity (14), adipogenesis (15), angiogenesis (16), extracellular matrix (ECM) dynamics 
(17), and inflammation (18).  Advancing our understanding about what dictates high vs. low FA 
Ra in obesity could lead to targeted approaches to attenuate elevated FA Ra, which could markedly 
improve metabolic health.  The primary purpose of this study was to determine factors that protect 





 Thirty sedentary, premenopausal women (n=25) and obese men (n=5) (BMI: 30-45 kg/m2) 
ages 18-40 years were recruited for this study.  Participants with coronary heart disease, type 2 
diabetes, hypertension, or clinically significant hypertriacylglycerolemia (plasma TG >150 
mg/dL) were excluded.  Participants were not taking regular medications known to effect 
metabolic processes, and some women were taking contraceptive medication.  All subjects were 
non-smokers, weight stable (±2 kg) for 6 months, and had not participated in any regularly planned 
exercise or physical activity for at least 6 months.   Body composition was assessed using dual 
energy X-ray absorptiometry (Lunar DPX DEXA Scanner).  Written, informed consent was 
obtained from all subjects before initiating participation and all study procedures were approved 
by the University of Michigan Institutional Review Board. 
 
Experimental Procedures 
 Subjects were admitted to the Michigan Clinical Research Unit at 0700h after an overnight 
fast.  We obtained a baseline blood sample and an ~100-200 mg subcutaneous adipose tissue 
sample from the abdominal region approximately 6 cm lateral to the umbilicus.  The sample was 
cleaned with saline, blotted dry, and quickly frozen in liquid nitrogen. At ~0900h, we began a 
constant-rate infusion of [1-13C]-palmitate (0.04 µmol/kg/min); after 45 min of infusion, three 
arterialized blood samples were obtained from a heated hand vein in 5-min intervals for 
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determination of FA Ra.  At ~1000h, we began a hyperinsulinemic-euglycemic clamp to assess 
peripheral insulin sensitivity using a primed 2-h insulin infusion at a rate of 100 mU/m2/min (19).  
This insulin infusion rate was selected to inhibit hepatic glucose production, even in insulin 
resistant subjects (20), allowing us to assess insulin sensitivity largely independent of the liver.  
Plasma glucose concentration was monitored every 5 minutes during the clamp study with a 
glucose autoanalyzer (Yellow Springs Instruments, Yellow Springs, OH), and glucose was infused 
at a variable rate to maintain plasma glucose concentration at each participant’s baseline fasting 
glucose concentration.  Insulin sensitivity was defined as the glucose infusion rate (GIR: mg/min) 
during the last 20 minutes of the hyperinsulinemic-euglycemic clamp (steady-state) divided by fat-
free mass (FFM, kg). 
 
Analytical Procedures 
Plasma fatty acid kinetics 
 The tracer-to-tracee ratio for plasma palmitate was determined by gas chromatography–
mass spectrometry (MSD 5973, Agilent Technologies, Wilmington, DE) as previously described 
(21).  Palmitate rate of appearance (Ra) into plasma was calculated using the Steele equation for 
steady-state conditions (22).  FA Ra was calculated by dividing palmitate Ra by the ratio of plasma 
palmitate to total plasma fatty acid concentration. 
 
Subject stratification 
 Subjects were divided into tertiles based on the magnitude of their FA Ra.  For our main 
comparisons, we examined differences between subjects that maintained a relatively low FA Ra 
despite being obese (LOW-FA; n=10) to those with a high FA Ra (HIGH-FA; n=10).   
 
Plasma measurements 
 Plasma glucose (Thermo Fisher Scientific, Waltham, MA), fatty acids (Wako Chemicals, 
Richmond, VA), TG (Sigma Aldrich, St. Louis, MO), and total cholesterol (Wako Chemicals, 
Richmond, VA) concentrations were measured using commercially available colorimetric assay 
kits. Plasma insulin concentration was measured by radioimmunoassay (EMD Millipore, St. 




mRNA expression  
 RNA was isolated from subcutaneous adipose tissue (~50mg) using a commercially 
available kit (Aurum total RNA fatty and fibrous tissue kit, Bio-Rad, Hercules, CA), quantified 
spectrophotometrically, and reverse transcribed (High-Capacity cDNA Reverse Transcription Kit, 
Thermo Fisher Scientific). Predesigned PrimeTime qPCR Assays (Integrated DNA Technologies, 
San Diego, CA) were used for mRNA analyses. Real-time quantitative PCR data was normalized 




 Microarray analysis of adipose tissue gene expression was performed by the University of 
Michigan DNA Sequencing Core following manufacturer recommendations.  RNA from the 5 
subjects with highest and lowest FA RA was hybridized to Human Gene ST 2.1 strips (Affymetrix, 
Santa Clara, CA).  The fold difference in gene expression between LOW-FA and HIGH-FA was 
determined with ArrayStar version 12.1 (DNASTAR, Rockville, MD).  The Upstream Regulator 
Module of Ingenuity Pathway Analysis (IPA) software (Qiagen, Redwood City, CA) was used to 
identify upstream transcriptional regulators potentially explaining differences in microarray gene 
expression. We performed gene set enrichment analysis with Pathway Analysis using Logistic 
Regression (LRPath: http://lrpath.ncibi.org/)(24) to test for predefined biologically relevant gene 
sets containing more significant genes than expected by chance between LOW-FA and HIGH-FA.  
The data discussed in this study have been deposited in NCBI's Gene Expression Omnibus and are 
accessible through GEO Series accession number GSE95777. 
 
Western blotting 
 Adipose tissue was homogenized in tissue lysis buffer (Cellytic MT cell lysis reagent, 
Sigma-Aldrich) with commercially available proteinase and phosphatase inhibitors (P8340, 
P5726, and P0044, Sigma-Aldrich).  Protein concentration was determined using the bicinchoninic 
acid method (Thermo Fisher Scientific).  Fifteen micrograms of protein were separated by SDS-
PAGE and transferred to nitrocellulose membranes.  Membranes were Ponceau stained to confirm 
equal loading.  Membranes were blocked, incubated in primary antibodies (Table 4-1) overnight 
at 4oC, washed, and incubated with appropriate secondary antibodies for 1 h. Blots were developed 
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using enhanced chemiluminescence (Clarity western ECL substrate, Bio-Rad), imaged, and 
quantified via densitometry (Image Lab software, Bio-Rad).   
 
Statistical Analysis 
 Simple linear regression was used to examine the relationship between FA Ra and insulin 
sensitivity.  Unpaired student’s t-tests were used to test for between group differences (LOW-FA 
vs. HIGH-FA) in all measured outcome variables. The linear regression and student’s t-tests were 
processed using Sigmaplot 13.0.  Statistical significance was defined as p<0.05.  Gene expression 
differences in the microarray data were determined in ArrayStar version 12.1 using a moderated t-
test (25). The fold difference values and p-values generated from ArrayStar were then used for 
directional tests in LRpath gene ontology analysis. For all immunoblot and gene expression 
analyses, we used Grubb’s outlier test (26) to detect outliers in the data sets using GraphPad 
statistical software (https://graphpad.com/quickcalcs/).  Using this test, we found one outlier value 
in each of the immunoblot analyses of pHSL/HSL, HSL, and CD36 and removed these data points.  
We also found and removed one outlier from each of the mRNA expression analyses for SORL1 




FA Ra and cohort stratification 
 As expected, FA Ra varied widely among our subjects (Figure 4-1A).  Subjects were 
stratified into FA Ra tertiles (Figure 4-1A), allowing for direct comparisons between subjects with 
the highest FA Ra values (“HIGH-FA”; ≥12.8 µmol/min/kg FM; n=10) vs. subjects with the lowest 
FA Ra values (“LOW-FA”; ≤8.7 µmol/min/kg FM; n=10).  Subjects with intermediate/moderate 
FA Ra values (“MOD-FA”; 8.8-12.7 µmol/min/kg FM; n=10) were excluded from our primary 
analyses (i.e., HIGH-FA vs. LOW-FA; Figure 4-1B), but were included in our correlational 
analyses across the entire cohort.  Expressing FA Ra relative to fat mass allowed us to evaluate 
differences in FA Ra independently of adipose tissue mass. Importantly, however, FA Ra remained 
significantly different (p<0.05) between HIGH-FA and LOW-FA even when not normalized 






 Age, body mass, and BMI were not different between groups (Table 4-2).  However, LOW-
FA had a significantly higher percentage of body fat (p<0.01) and lower FFM (p<0.01) compared 
with HIGH-FA (Table 4-2).  Although the HIGH-FA group contained 3 males and 7 females, while 
the LOW-FA contained only females (n=10), between-group differences in body composition 
were still evident even when comparing only female subjects in each group (Table 4-3). There 
were no significant differences in fasting plasma concentrations of insulin, glucose, fatty acids, 
TG, or total cholesterol (Table 4-4). 
 
FA Ra and insulin sensitivity 
 Subjects exhibited a wide range of insulin-mediated glucose uptake (i.e., insulin 
sensitivity) during the hyperinsulinemic-euglycemic clamp.  In agreement with our previous 
findings (8), we found a highly significant negative correlation between insulin sensitivity and FA 
Ra across the entire cohort (p<0.001; Figure 4-2A), and 50% of the variability in insulin sensitivity 
among subjects was explained by the magnitude of FA Ra (R2=0.50).  In addition, mean insulin 
sensitivity was nearly 85% greater in LOW-FA vs. HIGH-FA (p=0.003; Figure 2B). While the 
insulin sensitivity data presented in Figure 2 was normalized per FFM, it is important to note that 
insulin sensitivity was also significantly different between LOW-FA and HIGH-FA when not 
normalized to FFM (Table 4-5).  Furthermore, because the steady-state insulin concentration in 
plasma (SSI) during the clamp was not different between LOW-FA and HIGH-FA (Table 4-5), 
insulin sensitivity also remained significantly different (p=0.005) between the groups when 
normalized to SSI (GIR/SSI; Table 4-5).  To assess whether differences in the sex distribution in 
our cohorts (HIGH-FA: 7 women and 3 men; LOW-FA: 10 women and 0 men) influenced our 
findings, we also compared insulin sensitivity between only the female subjects in our groups, and 
found the differences in insulin sensitivity remained significant when the 3 men were removed 
from the HIGH-FA group (Table 4-5); Therefore, it appears that the inclusion of men in the HIGH-
FA group was not responsible for the observed differences in insulin sensitivity between the 







Lipolysis and esterification markers 
 We found a lower abundance (p=0.02) of phosphorylated hormone sensitive lipase (HSL) 
at serine 660 (HSLser660), a marker of HSL activity, and a trend (p=0.07) for a lower total HSL 
protein abundance in LOW-FA compared with HIGH-FA (Figure 5-3A and 5-3C).  However, 
there was no difference in HSL mRNA expression between groups (Figure 5-3D).  In contrast to 
HSL, neither protein abundance nor mRNA expression of adipose triglyceride lipase (ATGL) were 
different between groups (Figures 5-3A, 5-3C, and 5-3D).   Extracellular signal-regulated kinase 
(ERK) pathway activation, which increases lipolysis, was also significantly lower in LOW-FA vs. 
HIGH-FA (p-ERKThr202/Tyr204/ERK; p=0.05; Figures 5-3A and 5-3C).  We also found 3-fold greater 
protein abundance of glycerol-3-phosphate acyltransferase (GPAT) in LOW-FA compared with 
HIGH-FA (p=0.02; Figures 5-3B and 5-3C), despite no difference in GPAT1 mRNA expression 
(Figure 5-3D).  There were no differences in protein abundance or mRNA expression of 
diacylglycerol acyltransferase (DGAT) (Figures 5-3A-D).  
 
Markers of lipogenesis, adipogenesis, lipid storage, and transport 
 mRNA expression of factors involved in lipid droplet storage (PLIN1 and CIDEA) was not 
different between LOW-FA and HIGH-FA (Figure 5-3D).  mRNA expression of factors involved 
in lipogenic and adipogenic processes (i.e., PPARG, CEBPA, and SREBP1C) was also similar 
between LOW-FA and HIGH-FA (Figure 5-3D). Lastly, we found no differences between LOW-
FA and HIGH-FA in protein abundance of CD36, a primary fatty acid transporter (Figure 5-3B 
and 5-3C).   
 
LOW-FA vs. HIGH-FA gene expression profile  
 We performed gene ontology (GO) analyses on the microarray data from LOW-FA and 
HIGH-FA to identify novel alterations in biological pathways that may underlie the observed 
differences in FA Ra between LOW-FA and HIGH-FA.  Table 6 summarizes the three most highly 
upregulated and downregulated GO terms in LOW-FA compared to HIGH-FA that were 
statistically significant and biologically relevant.  LOW-FA had lower enrichment of pathways 
related to ECM structure, organization, and disassembly.  Surprisingly, the most highly 
	 75	 	
	
upregulated GO processes in LOW-FA were antigen receptor-mediated signaling, defense 
response, and lymphocyte differentiation, suggesting greater immune activity in LOW-FA adipose 
tissue.  Of the 413 statistically significant differentially (>2-fold) expressed genes in LOW-FA 
compared with HIGH-FA (Figure 5-4A), 210 genes were upregulated and 203 were downregulated 
in LOW-FA vs. HIGH-FA.  We examined the top genes (47 genes; Table 5-7that we thought may 
have an importantnovel involvement in adipose tissue metabolism and whole body metabolic 
outcomes.  Out of 47 genes, 40 were related to the adipose tissue immune response, while other 
candidate genes were related to fatty acid metabolism, ECM, and mitochondria.  Follow-up qPCR 
validation analyses performed for SORL1, SPP1, MEFV, BTLA, KLRK1, and CXCR1 (Table 5-7) 
confirmed significant differences in mRNA expression between HIGH-FA and LOW-FA for these 
6 genes (p<0.05; Figure 5-4B). 
 
Inflammation and fibrosis 
 IPA analysis predicted significant (p=0.04) downregulation of the stress/inflammatory 
SAPK/JNK pathway in LOW-FA vs. HIGH-FA (Figure 5-5A).  Follow-up western blot analysis 
confirmed significantly lower JNK pathway activation (p-JNKThr183/Tyr185/JNK) in LOW-FA 
compared with HIGH-FA (p=0.04; Figures 5-5B and 5-5C).  We found no differences between 
groups for other stress-related signaling pathways (i.e., p38 MAPK or STAT3; Figures 5-5B and 
5-5C).  There were also no differences in protein expression of MCP-1 or MAC2, a crude marker 
of macrophage abundance (Figures 5-5B and 5-5C).  qPCR analysis revealed no differences in 
mRNA expression of some canonical markers of inflammation (TNFA and MCP1) or COL1A1 
between LOW-FA and HIGH-FA (Figure 5-6A).  However, in agreement with the GO analysis, 
COL6A1 mRNA expression was lower in LOW-FA vs. HIGH-FA (p=0.009; Figure 5-6A), and 
COL6A1 expression was positively correlated with FA Ra (R2=0.29; p=0.003; Figure 5-6B). 
 
Discussion 
 Our observation that FA Ra from subcutaneous adipose tissue is associated with insulin 
resistance in obesity is consistent with previous work from our lab (8) and others (9).  Our findings 
suggest lower lipase activation, greater fatty acid esterification capacity, and alterations in ECM 
organization and fibrosis in subcutaneous adipose tissue may all contribute to the attenuated fatty 
acid release in our LOW-FA cohort, perhaps through an enhanced ability to sequester and store 
	 76	 	
	
fatty acids as TG within adipocytes.  In contrast to our hypothesis, our microarray data revealed 
upregulated markers of immune activity in subcutaneous adipose tissue from LOW-FA vs. HIGH-
FA.  Because insulin sensitivity was relatively high in our LOW-FA subjects, these findings from 
our microarray conflict with the overly simplistic notion that upregulated adipose tissue immune 
activity directly underlies the development of insulin resistance.  Furthermore, other novel 
mechanisms, perhaps involving SORL1, may be enhancing the ability of adipose tissue to suppress 
the release of fatty acids into circulation. 
 Excessive FA Ra from subcutaneous adipose tissue is causally linked with a host of cardio-
metabolic complications, including insulin resistance (27).  This is demonstrated clinically in 
patients with lipodystrophy, a condition characterized by an extraordinarily low capacity to store 
fatty acids in subcutaneous adipose tissue, leading to extreme insulin resistance (28).  
Lipodystrophic mice develop similar metabolic complications; however, these complications (e.g., 
insulin resistance, ectopic lipid deposition, etc.) can be reversed with transplantation of well-
functioning subcutaneous adipose tissue (29).  Although it may seem counter-intuitive, the ability 
to expand subcutaneous adipose tissue to accommodate nutrient oversupply may actually help 
prevent insulin resistance by enhancing the capacity to sequester fatty acids – thereby preventing 
excess fatty acid release and ectopic lipid deposition in insulin sensitive tissues (30). Our data 
suggest that LOW-FA subjects may have an enhanced ability to expand and store excess nutrients 
as TG in subcutaneous adipose tissue. While our data captures only a snapshot of the fat storage 
capacity in our subjects, other human studies that tracked long-term TG turnover and storage using 
deuterated water reported impaired TG synthesis and storage in subcutaneous adipose tissue of 
insulin-resistant obese adults (12).  Our data further support the importance of subcutaneous 
adipose tissue in the control of FA Ra and, subsequently, peripheral tissue insulin sensitivity. 
 Differences in the expression, abundance, and activation of enzymes controlling lipolysis 
and esterification among our subjects may contribute to the variability in their FA Ra and may 
impact whole-body insulin resistance.  Partial inhibition of lipolysis in obese mice through 
pharmacological or genetic manipulation of HSL resulted in lower fatty acid availability and 
improved insulin sensitivity without affecting fat mass (31).  Lower markers of lipolysis are also 
correlated with reduced indices of insulin resistance in obese humans, independently of fat mass 
(31).  In agreement, our LOW-FA group had lower markers of HSL activation (p-HSLser660/HSL) 
and ERK (p-ERKThr202/Tyr204/ERK) signaling, which are indicative of lower lipolytic activation (32, 
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33). Systemic fatty acid release from subcutaneous adipose tissue can also be attenuated by 
upregulated esterification, which can synthesize TGs from locally released fatty acids before they 
enter the circulation. Our finding that GPAT protein abundance (i.e., the enzyme catalyzing the 
first committed step of the esterification pathway (34)) was 3-fold greater in LOW-FA than HIGH-
FA suggests greater esterification capacity may have also contributed to a lower systemic FA 
release. Together, our findings suggest that obese adults who maintain relatively low FA Ra 
(LOW-FA) may have reduced activation of basal lipolysis and an increased capacity for fatty acid 
esterification compared with obese adults with high FA Ra. 
 Our finding that markers of ECM organization and assembly were lower in LOW-FA vs. 
HIGH-FA is very intriguing and among the most novel findings of our study.  Furthermore, to our 
knowledge, this is the first study demonstrating a strong direct correlation between FA Ra and 
collagen VI expression in human adipose tissue.  Therefore, ECM-mediated alterations in adipose 
tissue fatty acid metabolism may be an important contributor to the well-described relationship 
between excess accumulation of certain adipose tissue ECM components (including collagen VI) 
and insulin resistance in obesity (35).  Subcutaneous adipose tissue collagen VI expression has 
been found to be positively correlated with BMI, fat mass, and insulin resistance, and is 
upregulated during short-term overfeeding (36).  In agreement, mice lacking collagen VI were 
protected from high-fat diet induced insulin resistance (37).  The maintenance of insulin sensitivity 
in these mice was accompanied by larger, more hypertrophied adipocytes despite similar fat mass, 
indicating the lack of collagen VI may have allowed the adipocytes to expand with less constraint, 
providing improved capacity for fatty acid storage.  Having less subcutaneous adipose tissue 
fibrosis, resulting in enhanced adipocyte lipid storage capacity, lower mobilization of fatty acids, 
and a resultant lower ectopic lipid deposition is likely advantageous for maintaining insulin 
sensitivity in obese humans as well. 
 Fibrotic adipose tissue is also often accompanied by an elevated inflammatory profile (18, 
38), which is a key contributor to metabolic dysfunction in obesity (39).  However, despite 
evidence for higher adipose tissue fibrosis and lower insulin sensitivity in HIGH-FA vs. LOW-
FA, our finding that adipose tissue immune activity was lower in HIGH-FA compared with LOW-
FA conflicts with this notion.  The adipose tissue immune response is very complex, and 
inflammatory status clearly cannot be classified simply as “pro-inflammatory” and “anti-
inflammatory”.  The regulation of macrophages, neutrophils, lymphocytes, and T cell activity has 
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many redundant, overlapping mechanisms controlling whether these cells confer pathogenic or 
protective functions.  While macrophages are commonly linked to the development and 
maintenance of fibrosis, they are also involved in the inhibition and reversal of fibrosis (40, 41), 
which corroborates our data.  Although overall immune activity may be elevated, there could be a 
compensatory rise in mechanisms that mitigate the detrimental effects of increased immune 
activity on adipose tissue function, such as MEFV and BTLA.  MEFV plays a role in the 
degradation of several inflammasome components (42), while BTLA is involved in inhibiting the 
Th1 “pro-inflammatory” T cell response (43).  Furthermore, our LOW-FA group had higher 
mRNA expression of CXCR1, a powerful chemoattractant factor that activates neutrophils (44), 
and lower expression of SPP1, which is related to induction of the inflammatory response in 
obesity (45).  Unfortunately, without specific sorting and analysis of the adipose tissue immune 
cells, we can only speculate on the “protective” vs. “pathogenic” immune cell abundance and 
activity in the LOW-FA group.  Nevertheless, these data suggest an uncoupling of the immune 
inflammatory response and the development of insulin resistance in obese, yet otherwise healthy, 
individuals.  
Despite evidence of higher overall adipose tissue immune activity, SAP/JNK pathway 
activation was lower in adipose tissue from LOW-FA compared with HIGH-FA.  The SAPK/JNK 
pathway is activated in multiple tissues in obesity, including adipose tissue, and is implicated in 
orchestrating the relationship between inflammation and poor metabolic outcomes (46).  While the 
SAPK/JNK pathway can interfere with insulin signaling and promote insulin resistance (47), 
SAPK/JNK pathway activation in macrophages may also be important for controlling basal fatty 
acid release from adipose tissue.  For example, reducing JNK pathway activity in macrophages 
alters macrophage polarization and lowers the expression and release of pro-inflammatory 
cytokines that may cause excess FA Ra (48, 49). Therefore, the lower SAPK/JNK pathway 
activation in LOW-FA may explain why this group can maintain a lower FA Ra despite elevated 
overall immune activity.  Our findings demonstrate that preserving low JNK pathway activation 
in adipose tissue in obesity may be important for maintaining low FA Ra and preserving whole 
body insulin sensitivity in humans. 
 Another novel finding was the greater mRNA expression of sortilin-related receptor 
(SORL1) in adipose tissue from LOW-FA vs. HIGH-FA. SORL1 is best known for its role in the 
neurodegenerative processes involved in Alzheimer’s disease (50). However, Schmidt et al. 
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demonstrated an important role for SORL1 in modulating adipose tissue metabolic processes (51).  
For example, SORL1 overexpression in mice reduced TG hydrolysis, while inactivation of SORL1 
increased TG breakdown and fatty acid release from adipose tissue (51).  Perhaps the elevated 
SORL1 expression we found in subcutaneous adipose tissue from our LOW-FA subjects may be 
beneficial for sequestering fatty acids, reducing their release into the systemic circulation.  
 While our data provide important insight into possible mechanisms protecting some obese 
adults from developing insulin resistance, there are some limitations to this study.  First, although 
our findings identify several factors that may underlie differences in FA Ra among our cohort of 
obese subjects, our study does not directly address causation, which is always very challenging in 
human studies.  Second, because our measurements of FA Ra, gene expression, and protein 
abundance were performed on samples collected during the post-absorptive state, our conclusions 
do not address alterations in adipose tissue in the post-prandial state (i.e., insulin-stimulated).  
Relevant to this, we acknowledge that varying degrees of adipose tissue resistance to the anti-
lipolytic effects of insulin could also contribute to differences in FA Ra among our subjects.  
However, because our measurements were made in the post-absorptive state (i.e., when plasma 
insulin concentration was at its lowest point), the contribution of differences in adipose tissue 
insulin resistance on FA Ra was likely rather small in our study.  More importantly, we contend 
that ectopic lipid deposition (and its negative impact on whole-body insulin resistance) is primarily 
affected by the much higher FA Ra that occurs in the post-absorptive state, which is why we 
focused on assessing differences in FA Ra among our subjects after an overnight fast. 
Unfortunately, because we could not measure plasma catecholamines due to inadequate sample 
availability, we do not know if differences in circulating catecholamines may have also contributed 
to the differences in FA Ra between our groups.  Finally, we did not have adequate adipose tissue 
samples to perform histological measurements, which could provide more information about 
adipose tissue fibrosis and inflammation.  These measures will be incorporated in follow-up 
studies. 
 In conclusion, our findings support the importance of FA Ra from adipose tissue in 
modulating the degree of insulin resistance in obese adults.  Obese adults who can maintain low 
FA Ra may do so via reduced activation of lipolytic pathways (ERK and HSL) and enhanced fatty 
acid esterification.  The reduced activation of lipolytic pathways may also be mediated, in part, by 
increased SORL1 expression and/or reduced SAPK/JNK pathway activation. Furthermore, obese 
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adults who maintain low FA Ra have lower markers of fibrosis and ECM deposition, potentially 
enhancing their ability to store fatty acids as TG within adipocytes and protecting them from 
ectopic lipid deposition.  Expanding our understanding about what dictates systemic fatty acid 
release from adipose tissue may lead to the development of treatments or therapeutic interventions 
that can reduce and/or prevent insulin resistance in obesity. 
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Table 1: Primary antibodies               
α- phosphorylated extracellular signal-regulated kinase (p-ERK1/2Thr202/Tyr204) (Cell Signaling #9101) 
α- extracellular signal-regulated kinase (p-ERK1/2Thr202/Tyr204) (Cell Signaling #9102) 
α- phosphorylated hormone sensitive lipase (p-HSLser660) (Cell Signaling #4126) 
α- hormone sensitive lipase (HSL) (Cell Signaling #4107) 
α- adipose triglyceride lipase (ATGL) (Cell Signaling #2138) 
α- glycerol-3-phosphate acyltransferase 1 (GPAT1) (Sigma-Aldrich, PRS4613) 
α- diacylglycerol acyltransferase (DGAT) (Novus Biologicals, NB110-41487) 
α- phospho-signal transducer and activator of transcription 3 (p-Stat3Tyr705) (Cell Signaling, #9131) 
α- signal transducer and activator of transcription 3 (Stat3) (Cell Signaling, #4904) 
α- phospho-p38 MAPKThr180/Tyr182 (Cell Signaling #9211) 
α- p38 MAPK (Cell Signaling #9212) 
α- monocyte chemotactant protein 1 (MCP1) (Cell Signaling #2720) 
α- Galectin-3 (MAC2) (Abcam Inc., ab2785) 
α- fatty acid translocase (FAT/CD36) (Abcam Inc., EPR6573) 
 
















  HIGH-FA LOW-FA 
Sex (M/F) 3/7 0/10 
Age (y) 28 ± 2 34 ± 3 
BMI (kg/m2) 36 ± 1 37 ± 1 
Mass (kg) 106 ± 6 99 ± 3 
Fat mass (kg) 45 ± 5 52 ± 2  
Fat free mass (kg) 61 ± 4 47 ± 1* 
Body Fat (%) 44 ± 2 53 ± 1* 
BMI: Body Mass Index. * significant difference 
compared to HIGH-FA, p<0.05. Data presented as 
Mean ± SD. 
 

















  HIGH-FA LOW-FA 
Sex (M/F) 0/7 0/10 
Age (y) 30 ± 2 34 ± 3 
BMI (kg/m2) 37 ± 1 37 ± 1 
Mass (kg) 102 ± 7 99 ± 3 
Fat mass (kg) 48 ± 5 52 ± 2  
Fat free mass (kg) 54 ± 3 47 ± 1* 
Body Fat (%) 47 ± 2 53 ± 1* 
BMI: Body Mass Index. * significant difference compared to 
HIGH-FA, p<0.05. Data presented as Mean ± SD. 
 






















  HIGH-FA LOW-FA 
Glucose (mM) 4.9 ± 0.2 4.6 ± 0.1 
Insulin (µU/mL) 21.3 ± 3.8 18.7 ± 2.3 
NEFA (µM) 606 ±  61 493 ± 54 
Triglycerides (mg/dL) 73 ± 13 49 ± 8 
Total cholesterol (mg/dL) 161 ± 7 146 ± 11 
Data presented as Mean ± SD.	

























     
A  HIGH-FA (n=10) 
LOW-FA 
(n=10) P value 
Glucose infusion rate (GIR: mg/min) 446 ± 182 610 ± 128* 0.04 




1.4 ± 0.5 
 
 






 B HIGH-FA (n=7; all women) 
LOW-FA  
(n=10; all women) P value 
Glucose infusion rate (GIR: mg/min) 429 ± 145 610 ± 128* 0.02 
Steady-state insulin (SSI: µU/ml) 321 ± 87 287 ± 64 0.38 
GIR/SSI 1.3 ± 0.4 2.2 ± 0.5* 0.002 
Values are Means ± SD. GIR: Glucose infusion rate; SSI: steady-state insulin concentration in plasma.                       
* Significantly greater than HIGH –FA, P<0.05.  
 























GO:0022617 extracellular matrix disassembly 6.04E-06 




GO:0030198 extracellular matrix organization 6.04E-06 
APP1, FN1, TIMP1, 
COL1A2, ITGA3, CD151, 
SERPINH1, COL6A1, 




GO:0043062 extracellular structure organization 6.04E-06 
APP1, FN1, TIMP1, 
COL1A2, ITGA3, CD151, 
SERPINH1, COL6A1, 




GO:0050851 antigen receptor-mediated signaling pathway 4.57E-04 LCK, CD38, UBA52 up 
GO:0098542 defense response to other organism 0.001437458 
LCK, DDX58, ISG15, 




GO:0030098 lymphocyte differentiation 0.00292656 LCK, ATP7A, POU1F1, CD27, BCL3, SLC46A2 up 
 
 















LOW-FA relative to HIGH-FA 




metabolism   AADAC Arylacetamide Deacetylase 0.24 
   FFAR3 Free Fatty Acid Receptor 3 0.40 
    SORL1 Sortilin-related receptor 2.71 
Extracellular 
Matrix   MMP9 Matrix Metalloproteinase 9 0.41 
   MMP7 Matrix Metalloproteinase 7 0.45 






DRB1 Major Histocompatibility Complex, Class II, DR Beta 1 0.35 
   
HLA-
DQB1 Major Histocompatibility Complex, Class II, DQ Beta 1 2.88 
   LILRA Leukocyte Immunoglobulin Like Receptor A1 2.40 
  T cell CCL19 Chemokine (C-C Motif) Ligand 19 0.48 
   TRBV11 T Cell Receptor Beta Variable 11-1 0.46 
   TRGJP2 T Cell Receptor Gamma Joining P2 3.80 
   TRGJ2 T cell receptor gamma joining 2 3.03 
   TAGAP T-Cell Activation RhoGTPase Activating Protein 2.79 
   TRAJ17 T cell receptor alpha joining 17 2.39 
   TRAT1 T Cell Receptor Associated Transmembrane Adaptor 1 2.35 
   TRAJ49 T cell receptor 2.35 
   TRAJ14 T cell receptor 2.19 
   TRAJ42 T cell receptor 2.19 
   TRAJ47 T cell receptor 2.18 
  
T cell 
activation NKG7 Natural Killer Cell Granule Protein 7 2.77 
   BTLA B and T Lymphocyte Associated 2.73 
   TXK Non-receptor tyrosine kinase 2.31 
   KLRK1 killer cell lectin like receptor K1 2.20 
   GZMA Granzyme A 3.15 
   CD3D CD3 2.16 
  
"Anti" 
inflammatory MEFV Mediterranean Fever 2.53 
   SPP1 Secreted Phosphoprotein 1  0.35 
   LBP Lipopolysaccharide Binding Protein 0.43 
   FPR3 Formyl Peptide Receptor 3 0.54 
  Neutrophils CSF3R Colony stimulating factor 3 2.36 
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   CXCR1 Chemokine (C-X-C Motif) Ligand 1 4.20 
   VNN2 Vanin 2 3.60 
  
Lymphocyte 
related SELL Selectin L 3.40 
   FPR1 Formyl Peptide Receptor 1 2.73 
   S1PR4 Shpingosine-1-phosphate receptor 4 2.44 
   MS4A1 Membrane Spanning Protein 4 A1 2.55 
  
Cytokines / 
other IL23A Interleukin 23 Subunit Alpha 3.15 
   IL18 Interleukin 18 receptor accessory protein 2.33 
   CLEC1B C-Type Lectin Domain Family 1 Member B 3.01 
   RNASE2 Ribonuclease A Family Member 2 2.75 
   GBP5 Guanylate Binding Protein 5 2.75 
   IFIT1B Interferon Induced Protein 2.47 
   DEFA Defensin 2.42 
   EMR3 
EGF-like module-containing mucin-like hormone 
receptor-like 3  2.38 
    MNDA Myeloid Cell Nuclear Differentiation Antigen 2.36 
Mitochondria    YME1L1 YME1 Like 1 ATPase 3.15 
 
 



















Figure 4-1: FA Ra variability across all subjects. (A) FA Ra across the entire cohort (n=30) 
normalized to FM (B) in HIGH-FA (black circles) vs LOW-FA (white circles) normalized to FM 
(C) in HIGH-FA vs LOW-FA expressed as total FA Ra (D) in HIGH-FA vs LOW-FA 

















Figure 4-2:  FA Ra and insulin sensitivity. (A) Correlation between insulin-mediated glucose 
uptake during the clamp (insulin sensitivity) and FA Ra (LOW-FA [n=10; white circles], MOD-
FA [n=10; half black, half white circles], HIGH-FA [n=10; black circles]) (B) Insulin sensitivity 







Figure 4-3: Markers of lipolysis, esterification, and fatty acid uptake. (A) Relative protein 
abundance of proteins related to lipolysis normalized to HIGH-FA. (B) Relative protein 
abundance of proteins related to esterification and fatty acid uptake expressed relative to HIGH-
FA. (C) Representative images for western blotting analysis of proteins related to lipolysis, 
esterification, and fatty acid uptake. (D) mRNA expression of factors related to lipolysis, 
esterification, lipogenesis, and fatty acid storage in LOW-FA (n=9; white circles) compared with 
HIGH-FA (n=9; black circles).  Expression values were normalized to the mean of the 
housekeeping genes PPIA and B2M and then expressed relative to HIGH-FA. Data expressed as 








Figure 4-4: Microarray and gene expression analysis of adipose tissue. (A) Heatmap 
representing genes 2-fold differentially expressed in LOW-FA compared with HIGH-FA. (B) 
qPCR validation of mRNA expression of  6 genes found to be greater than 2-fold different in 
LOW-FA (n=9, white circles) compared with HIGH-FA (n=9, black circles). Expression values 
were normalized to the mean of the housekeeping genes PPIA and B2M and then expressed 

















Figure 4-5: SAPK/JNK and stress/inflammatory pathway activation. (A) Ingenuity Pathway 
Anlaysis identified the SAPK/JNK pathway to be significantly downregulated in LOW-FA 
compared with HIGH-FA (p=0.04) (B) Relative protein abundance of proteins related to stress 
pathway activation and inflammation expressed relative to HIGH-FA (LOW-FA n=8, white 
circles; HIGH-FA n=9, black circles). (C) Representative blots.  Data expressed as MEAN ± SD. 





Figure 4-6: Markers of inflammation and fibrosis. (A) mRNA expression of factors related to 
inflammation and fibrosis in LOW-FA (n=7-9; white circles) compared with HIGH-FA (n=7-9; 
black circles). Expression values were normalized to the mean of the housekeeping genes PPIA 
and B2M and then expressed relative to HIGH-FA. Data expressed as MEAN ± SD. *P<0.05 vs 
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Aerobic exercise elevates markers of angiogenesis and alternative macrophage activation in 
the subcutaneous adipose tissue of overweight to obese adults 
 
Abstract 
Alterations in the inflammatory state, metabolic function, and structure of subcutaneous adipose 
tissue (SAT) can greatly impact the development of insulin resistance in obesity. Exercise is 
often prescribed to improve metabolic health in obesity, but the effects of exercise on SAT are 
not well known. The primary aims of this study was to examine the effects of exercise on mRNA 
expression of markers of lipid metabolism (ATGL, HSL, DGAT, GPAT, PPARG, SREBP1c, 
PLIN1), inflammation (TNFA, IL1B, NLRP3, MCP1, CD11C, CD206), fibrosis (COL6A1, 
COL1A1), and hypoxia/angiogenesis (HIF1A, VEGF, CD31, GLUT1) in SAT, as well as 
adipocyte cell size. We recruited overweight-to-obese adults who exercise regularly (ACTIVE: 
n=8) or were sedentary (SED: n=12). The groups were well-matched for age (27±1 vs. 24±2 y), 
BMI (29±1 vs. 27±1 kg/m2), and body composition (30±1 vs 29±1 % body fat), but as expected, 
cardiorespiratory fitness was greater in ACTIVE vs. SED (VO2peak: 51±3 vs. 42±1 ml/kg 
FFM/min; p=0.03). Abdominal SAT biopsy samples were obtained before and 1hr after 60min of 
aerobic exercise (~65% VO2peak). The exercise session increased SAT mRNA expression of 
VEGFA, an important regulator if angiogenic processes, in both groups.   In addition, SAT from 
ACTIVE subjects had a higher mRNA expression of the endothelial cell marker, CD31 
compared with SED. This elevation is suggestive an increase SAT capillarization in our habitual 
exercisers, which may be the cumulative effect of the transient increases in VEGFA with each of 
their regular exercise sessions.  We also magnetically sorted CD14+ immune cells from SAT 
samples and found that expression of IL6 was elevated in ACTIVE compared with SED.  
Exercise did not affect the expression of other inflammatory factors, markers if lipid metabolism, 
or extracellular matrix. In conclusion, exercise initiates increases in factors related to angiogenic 







Regular exercise is known to have overall health benefits and is often prescribed to 
combat obesity-related metabolic complications that can lead to metabolic diseases, such as type 
2 diabetes (T2D) and cardiovascular disease (CVD) (1). Elevated cardiorespiratory fitness is 
associated with reduced CVD risk factors, as well as reduced incidence of CVD and T2D (2, 3). 
While most of the focus on exercise adaptations that benefit metabolic health has centered on 
changes in skeletal muscle, exercise-induced changes in other tissues and organs may also 
contribute to the metabolic health effects of exercise (4). In particular, adaptations to exercise in 
adipose tissue may be important for mediating whole body metabolic outcomes since it is now 
well-recognized that adipose tissue health and function plays a prominent role in dictating 
obesity-related metabolic complications (5-7). 
 While the adipose tissue can actively secrete peptides (i.e. adipokines) that may have 
important systemic effects, complexities associated with the regulation of lipid storage within 
adipocytes can also have profound metabolic consequences (8-10).  Limitations in the lipid 
storage capacity of adipose tissue can expose peripheral tissues to high levels of fatty acids, 
which can impair insulin signaling (11-13) and disrupt other cellular processes (14, 15). Several 
factors within adipose tissue are postulated to be important for determining its lipid storage 
capacity including lipase and esterification enzymes (16, 17), adipocyte cell size (18), 
extracellular matrix structure (19, 20), capillarization (21), and inflammation (22, 23). Several 
studies have reported beneficial effects of exercise on adipose tissue inflammation, fibrosis, and 
adipose tissue insulin sensitivity in humans, but these studies are confounded by a reduction in 
body fat mass that accompanied their exercise interventions(24-27), and even modest weight loss 
can profoundly impact adipose tissue and whole body metabolic outcomes (25, 27-29).  
However, recent animal studies show promising evidence for beneficial direct effects of exercise 
on adipose tissue structure and metabolic function (30-34). 
 It remains unclear whether exercise, acute or chronic, causes beneficial adaptations in 
adipose tissue that can improve obesity-related metabolic complications in humans. Therefore, 
the purpose of this study was to examine the effects of acute and habitual exercise training on the 
expression of factors related to adipose tissue fatty acid release and storage (e.g., lipolysis, 
esterification, lipogenesis, adipogenesis), the composition of the extracellular matrix, 
angiogenesis, adipose tissue cell size, and inflammation in adipose tissue. We hypothesized that 
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acute exercise will stimulate factors that may lead to improved metabolic health and function of 
the adipose tissue, and that habitual exercisers will have markers of improved metabolic health in 





A total of 20 overweight-to-mildly obese individuals, (body mass index [BMI]: 25-35 kg/m2) 
between the ages of 18 and 40 were recruited for the study.  Subjects completed a comprehensive 
behavior survey/questionnaire, and were categorized into the different cohorts based on their 
self-reported habitual physical activity behavior. Twelve of the subjects were non-exercisers 
(SED: n=12) while 8 subjects exercised regularly (ACTIVE: n=8) (i.e. at least 4 days/wk of 
aerobic/cardiovascular exercise for 30-60min/session at moderate and vigorous intensities  
Participants were not taking any medication known to effect metabolic outcomes.  All 
participants were non-smokers and weight stable (within ± 2kg for ≥ 6 months).  None of the 
subjects had any history of metabolic or cardiovascular disease that would impact study 
outcomes. Written, informed consent was obtained from all subjects before initiating 




Maximal oxygen consumption (VO2max) 
Subjects completed a graded exercise test that involved a 4 minute warm-up, followed by an 
increase in exercise workload (increased speed and grade on treadmill or increased resistance on 
bike) every 1-2 minutes until the subject reached volitional fatigue. The participant had the 
choice to perform the test on either a stationary bike (Lode ergometer) or treadmill, and 
importantly, the modality of exercise chosen was the exercise modality used for the experimental 
procedures.  Maximal oxygen consumption and maximal heart rate were recorded and used for 





Oral glucose tolerance test (OGTT) 
Subjects arrived at the laboratory after an overnight fast to assess their glucose tolerance. 
Subjects who exercise regularly abstained from exercise for 3 days before the OGTT.   Subjects 
drank a flavored solution containing 75 grams of glucose (FisherbrandTM GTT Beverage) and 
then we collected blood from an intravenous (IV) catheter inserted in to their arm vein every 15 
minutes for 3 hours.  Blood samples were centrifuged at 2000rpm at 4oC for 15 minutes, and 




Body composition was assessed using hydrostatic weighing (35).  Briefly, subjects were weighed 
underwater after exhaling all air except residual lung volume using a scale attached to a chair in 
the water.  Water temperature was maintained at 37oC.  Residual lung volume was estimated 
using appropriate equations based on age, stature, and body mass.  The appropriate Siri equation 
was then used to estimate percent body fat. 
 
Experimental protocol 
All subjects arrived to the laboratory in the morning of testing after an overnight fast (~0700h, 
~10h fast).  Furthermore, subjects who were regular exercisers refrained from exercise for 3 days 
prior to their experimental trial.  After resting quietly for 30 minutes, we collected a baseline 
blood sample followed by collection of an abdominal subcutaneous adipose tissue sample using 
a needle aspiration method.  This aspiration procedure involves injection of local anesthetic (2% 
lidocaine) in a region about 5cm lateral to the umbilicus.  Adipose tissue is removed using a 16g 
needle with suction applied with a 10cc syringe.  A portion of the adipose tissue biopsy was 
cleaned with saline, dried, and quickly frozen in liquid nitrogen, while a separate portion of 
cleaned sample was placed in phosphate buffered saline for separation of mature adipocytes and 
the stromal vascular fraction. Subjects then exercised on a treadmill or cycle ergometer for 1 
hour at a moderate intensity (approximately 65%of their pre-determined VO2max).  Exactly 1h 
after exercise, we repeated the adipose tissue biopsy procedure along with a final blood draw.  






Plasma substrate measurements 
Plasma glucose (Thermo Scientific, Waltham, MA, USA) and fatty acid (Wako Chemicals USA, 
Richmond, VA, USA), concentrations were measured using commercially available colorimetric 
assay kits. Plasma insulin concentration was measured with a chemiluminescent immunoassay 
method (Siemens IMMULITE 1000, Flanders, NJ, USA). 
 
Isolation of mature adipocytes and resident immune cells. 
In order to differentiate changes in the various cell populations in the adipose tissue in response 
to exercise, we separated the mature adipocytes from the stromal vascular fraction.  First, the 
adipose tissue was digested in Collagenase Type I (1mg/ml) in Hank’s Balanced Salt Solution 
(HBSS) while gently rocking at 37oC for one hour.  The digested tissue was strained through a 
300µm nylon mesh filter to remove debris.  The digested tissue was then be allowed to sit until 
all of the mature adipocytes floated to the top of the digested tissue.  The SVF was then removed 
from underneath of the adipocytes.  The mature adipocytes were used for RNA expression and 
cell sizing analysis (described below).  The SVF was spun and pelleted at 500g for 7 minutes to 
allow for the removal of the supernatant and any residual mature adipocytes remaining.  After 3 
washes in PBS supplemented with 2% fetal bovine serum (to assist with maintaining cell 
viability), a commercially available immunomagnetic bead sorting kit (EasySep Human CD14 
Positive Selection Kit, #18058, Stem Cell Technologies) was used to isolate the immune cell 
fraction from the SVF.  The cell surface marker CD14 has been shown to be a marker specific to 
the macrophage population (36, 37), therefore, we used this marker as a means for identifying 
and isolating the adipose tissue macrophage population.   
 
Adipose tissue mRNA expression  
For isolation of RNA, sections of subcutaneous adipose tissue (~50mg), mature adipocytes, and 
CD14+ cells were homogenized in RNA Stat-60 (Tel-Test Inc., Friendswood, TX).  RNA was 
isolated by chloroform extraction using a commercially available RNA isolation kit (Aurum total 
RNA fatty and fibrous tissue kit, Bio-Rad Laboratories, Inc.) and quantified 
spectrophotometrically. Reverse transcription was performed with 0.25µg of total RNA with the 
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High-Capacity cDNA RT kit (4368813, Life Technologies, Grand Island, NY). Real-time 
quantitative PCR was used to assess the mRNA expression levels of the genes listed in Table 5-
1.  Primer and probe sequences were designed for each gene’s mRNA sequence using 
predesigned PrimeTime qPCR Assays (IDT). The qPCR data was normalized to expression of 2 
housekeeping genes (peptidylprolyl isomerase A (PPIA) and beta-2-microglobulin (B2M)) using 
the -∆Ct method (38) and expressed as fold induction (2-∆Ct) of mRNA expression. 
	
Adipocyte size 
We quantified the distribution of adipocyte cell size by imaging mature adipocytes using a 
brightfield microscope.  A small portion of the isolated mature adipocytes (isolation described 
above) was added to an equal volume of formalin, gently mixed, and stored at 4oC.  When ready 
to image the cells, 10µl of the suspension of fixed adipocytes were added to 20µl of mounting 
medium on a microscope slide and covered with a coverslip.  Quantification of cell size was then 




Index of whole body insulin sensitivity 
 Plasma glucose and insulin concentrations measured before and during the OGTT were used to 
assess insulin sensitivity using the Matsuda Composite Index (40).  The Matsuda Composite 
Index has been found to be a reasonably accurate marker for insulin sensitivity when compared 
with the hyperinsulinemic-euglycemic clamp (40). 
 
Statistical analysis 
We used a two-way ANOVA with Tukey post-hoc analysis to assess significant differences in 
mRNA and adipocyte cell size between groups and in response to the single session of exercise. 
A Student’s t-test was used to compare glycerol release in mature adipocytes and adipose 








There were no differences age, body mass, body mass index (BMI), body fat percentage, fat 
mass (FM), or fat free mass (FFM) between SED and ACTIVE (Table 5-2).  In addition, there 
were no differences in markers of insulin sensitivity or glucose tolerance between the groups 
(Table 5-2).  As expected, however, ACTIVE had a higher VO2peak compared with SED (52±3 
vs. 42±2 ml/kg FFM/min, respectively; p=0.01) (Table 5-2).  
 
Adipose tissue  
Markers of angiogenesis, vascularization, and hypoxia 
The acute exercise session significantly increased (p<0.05) mRNA expression of VEGFA (Figure 
5-2A). Because VEGFA is a primary mediator of increased angiogenesis (41), we interpret this 
finding to suggest acute exercise may trigger an increase in angiogenesis in adipose tissue.  In 
line with this finding, we found the expression of the endothelial cell marker, CD31, to be 
elevated (p<0.05) in our regular exercisers (i.e., ACTIVE > SED; Figure 5-2B).  mRNA 
expression of HIF1A was also greater in ACTIVE compared with SED, but there was no effect 
of acute exercise on HIF1A expression in either group (Figure 5-2C). mRNA expression of 
GLUT1, a marker for elevated hypoxia, was not different between groups, nor was it altered after 
acute exercise (Figure 5-2D).   
 
Markers of inflammation 
mRNA expression of all genes measured related to inflammation (TNFA, IL1B, NLRP3, MCP1, 
CD11C, CD206, CD163) were not different between ACTIVE vs. SED before exercise or 1 hour 
after the exercise session in the whole tissue homogenate (Figure 5-3). In most whole tissue 
samples, the mRNA expression of IL6 was undetectable or had ΔCt values higher than 35, 
therefore we did not use this data. The expression of IL1B, NLRP3, MCP1, CD11C, and CD206 
were also not different between groups in the CD14+ enriched fraction (Figure 5-4). However, 
IL6 expression in the CD14+ enriched fraction was 4-fold greater in ACTIVE vs. SED (main 
effect for group; p<0.05) (Figure 5-4G).  While the acute session of exercise did not significantly 
affect any of the inflammatory markers we measured in either the whole tissue homogenate 
(Figure 5-2) or the CD14+ enriched fraction (Figure 5-3), we did find trends for the exercise 
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session to lower the expression of TNFA (p=0.09) and IL6 (p=0.055) and in the CD14+ fraction 
(Figures 5-4A and 5-4G).   
 
Lipid metabolism 
In vitro and ex vivo lipolytic rates (both unstimulated and isoproterenol-stimulated) measured in 
mature adipocytes and adipose tissue explants collected before exercise were largely similar in 
ACTIVE and SED (Figure 5-5).  Importantly, the acute exercise session blunted isoproterenol-
stimulated glycerol release in explants from ACTIVE subjects (Figure 5-5B), but this effect did 
not quite reach statistical significance in SED.  Examining the acute effects of exercise in 
ACTIVE and SED combined, we found that acute exercise significantly lowered isoproterenol-
stimulated glycerol release in both mature adipocytes and adipose tissue explants (p<0.05; 
Figures 5-5C and 5-5D).  There were no effects of acute exercise on the expression of genes 
related to lipolysis (ATGL, HSL), esterification (GPAT, DGAT), lipid storage (PLIN1, CIDEA), 
lipogenesis, or adipogenesis (SREBP1C, PPARG) in mature adipocytes extracted from adipose 
tissue samples collected 1h after exercise compared with before exercise in either ACTIVE or 
SED, and no difference in the expression of any of these factors between groups (Figure 5-6). 
 
Extracellular matrix and adipocyte cell size 
mRNA expression of COL6A1 and COL1A1 were similar in ACTIVE and SED subjects before 
exercise or 1 hour after the exercise session (Figure 5-7).  Additionally, we found no differences 
in the proportion of small adipocytes (<5000µm2) or in the average adipocyte size between the 





The main findings of this study suggest that exercise may trigger an increase in 
angiogenesis and capillarization in the subcutaneous adipose tissue of overweight and obese 
subjects. More specifically, a single session of aerobic exercise increased adipose tissue mRNA 
expression of VEGFA in both habitual exercisers and non-exercisers. An elevation in VEGFA 
after each exercise session may underlie an increased adipose capillarization in the habitual 
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exercisers, as suggested by higher expression of the endothelial cell marker, CD31 in adipose 
tissue from this group. Habitual exercisers also had a higher expression of IL6, a cytokine 
important for alternative macrophage activation, in the CD14+ enriched fraction of their adipose 
tissue. We did not find any other effects of acute or habitual exercise on our measured markers of 
adipose tissue fibrosis, adipogenesis, adipocyte cell size, or other markers of inflammation. 
Overall, our data suggests that exercise may initiate angiogenic processes and cause alternative 
macrophage activation in the subcutaneous adipose tissue of obese adults. 
Inadequate adipose tissue vascularization and hypoxia have been implicated as primary 
mediators of metabolic complications in obesity (42, 43).  Angiogenic processes are stimulated 
by reductions in oxygen tension and nutrient availability, which signal for vessel formation 
primarily through the VEGF family of proteins (44). The VEGF family of proteins is considered 
to be one of, if not the most important regulators of endothelial cell growth (41). Binding of 
VEGF to VEGF receptors on endothelial cells initiates a signaling cascade that promotes 
proliferation, migration, and vessel formation (41). While we did not observe differences in 
baseline measures of VEGFA between ACTIVE and SED, a single session of aerobic exercise 
increased VEGFA mRNA in both groups. Repeated exercise bouts in the ACTIVE group that 
elevate VEGFA gene expression may lead to stable increases in capillarization as evidenced by 
the elevated mRNA expression of CD31 in ACTIVE compared with SED. To our knowledge, 
only one study has examined whether exercise training without weight loss can alter 
capillarization in adipose tissue in obese humans (45). Walton et al. (45) reported that 12 weeks 
of aerobic exercise training in a group of insulin-sensitive obese adults was sufficient to increase 
CD31 mRNA expression and the density of capillaries in subcutaneous adipose tissue. 
Interestingly, Walton et al., (45) found no effect of exercise training on adipose tissue capillary 
density in their subjects who were “insulin resistant”. The average BMI for their insulin resistant 
cohort was ~35kg/m2, compared with ~26kg/m2 in their insulin sensitive cohort, therefore it is 
possible that exercise has different effects on the angiogenic processes in the adipose tissue of 
obese adults who are more obese and/or insulin resistant. The reason why exercise may not 
augment angiogenesis and capillarization in obese adults with insulin resistance is not clear. 
Perhaps the higher fat mass in the insulin resistant cohort has higher inflammation, fibrosis, or 
other metabolic abnormalities that may inhibit angiogenic processes. 
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Hypoxia in adipose tissue can increase inflammation and disrupt normal glucose and lipid 
metabolism in obesity (42, 46). Our finding that adipose tissue GLUT 1 expression (i.e., a 
surrogate marker of hypoxic conditions and changes in oxygen tension (47-49)was not different 
between our habitual exercisers and non-exercisers provides crude data to suggest that adipose 
hypoxia may not be different between these groups. We recognize that this evidence for no 
difference in hypoxia between our groups may appear to contradict our findings suggesting 
higher capillarization in our habitual exercisers, but because our subjects were only over weight-
to-mildly obese (average BMI ~28kg/m2) it is possible that the differences in capillarization may 
not manifest into measurable differences in markers of hypoxia in this population.  
HIF1-α is a transcription factor that is also tightly linked with hypoxia. In response to 
reduced oxygen tension, HIF-1α targets VEGFA (44, 50), along with promoting inflammation 
and fibrosis (44, 51, 52). Thus, HIF1-α signaling can upregulate angiogenic processes, in part 
through VEGF signaling, but simultaneously increases expression of inflammatory factors that 
may cause insulin resistance and metabolic disturbances. Although we found adipose tissue 
HIF1A mRNA expression to be greater in our habitual exercisers compared with non-exercisers, 
it is the protein abundance and cellular localization of HIF1-α that are functionally linked to 
hypoxia, rather than its mRNA expression. In fact, in vitro studies demonstrate that induction of 
hypoxia in 3T3-L1 cells has no effect on HIF1A mRNA (53), while in human primary adipocytes 
hypoxia reduced HIF1A mRNA expression (49). In both of these studies (49, 53), the abundance 
and transcriptional activity of HIF-1α protein was increased during hypoxic conditions, further 
demonstrating the lack of connection between HIF1A mRNA, HIF-1α activity, and hypoxic 
conditions. Unfortunately, tissue limitations in our study prevented us from making 
measurements of HIF-1α protein content and localization, so we could not assess differences in 
the abundance or functional activity of HIF-1α. It remains inconclusive based whether the 
measured difference in HIF1A mRNA in our study had any indirect impact on our metabolic 
outcomes. 
Although it may seem counter-intuitive, an enhanced ability to effectively expand 
subcutaneous adipose tissue during periods of nutrient excess may actually help attenuate the 
metabolic complications commonly associated with weight gain and obesity. This phenomenon 
has been referred to as the “Expandability hypothesis” (9, 10). A major underlying premise of 
the expandability hypothesis is that an enhanced ability to effectively store excess energy in 
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adipose tissue will help sequester excess fatty acids, reducing systemic fatty acid flux into the 
systemic circulation - and thereby help prevent excessive fatty acid uptake into insulin-
responsive peripheral tissues (e.g. skeletal muscle and liver). Importantly, this hypothesis does 
not imply that gaining weight and increasing adiposity is healthful, but rather that when 
experiencing episodes of weight gain, subcutaneous adipose tissue that can more effectively 
store the excess energy may provide protection from metabolic disorders such as insulin 
resistance. The vast majority of adipose tissue expansion is due to adipocyte hypertrophy (i.e., 
increasing fat cell size), and the structure and composition of the extracellular matrix (ECM) 
may dictate the ability of adipocytes to adequately expand and store nutrients (54). 
Collagen VI is a primary form of collagen found in adipose tissue (55), and the 
magnitude of collagen VI expression in adipose tissue is linked to insulin resistance (55). In 
agreement, we found COL6A1 expression to be proportional to systemic fatty acid release from 
adipose tissue in STUDY #2 of my dissertation, reinforcing the notion that fibrosis in adipose 
tissue may contribute to the development of whole body insulin resistance. It has been suggested 
that high abundance of collagen VI can restrict adipocyte expansion – conversely, lower 
abundance of collagen VI allows the adipocyte to expand more freely, and thereby more 
effectively store fatty acids during episodes of nutrient excess (55). Interestingly, exercise may 
help modify adipose ECM. It has been reported that when compared with sedentary mice on a 
high fat diet, mice that exercised while eating the same high fat diet exhibited lower fibrosis (33). 
In a similar study by Kawanishi et al., exercising mice had larger adipocytes compared with their 
non-exercising counter-parts on a high-fat diet, suggesting their lower adipose fibrosis may allow 
adipocytes to expand more freely to accommodate the excess nutrients  (32). We did not find any 
differences in COL6A1 or COL1A1 between our regular exercisers and non-exercisers suggesting 
that exercise training may not have the same effect in human subjects under weight stable 
conditions. However, because the mice in Kawanishi, et al. (32, 33) were exercising and gaining 
weight simultaneously it is possible that these adaptations may occur only with the stimuli of 
exercise together with nutrient excess. 
Although adipocyte hypertrophy is the primary mechanism for storing excess energy in 
adipose tissue, adipose tissue may also expand through hyperplasia and create new adipocytes to 
accommodate the increased need for lipid storage. During exercise, there are several factors 
released into the circulation during and/or after exercise (e.g. fatty acids, IGF-1, cortisol) that are 
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known activators of adipogenic processes, so we hypothesized that exercise may upregulate 
expression of factors critical to adipogenesis (e.g. PPARG and CEBPA). Stanford et al. (34) 
demonstrated that mice exposed to a short-term endurance exercise training program without 
weight loss greatly increased their abundance of small adipocytes, suggesting enhanced 
adipogenesis. In contrast to our hypothesis, however, we did not find differences in expression of 
some critical regulators of adipogenesis or in the adipocyte cell size between ACTIVE and SED. 
Our current data set in overweight and obese adults that are metabolically healthy suggests 
exercise may not have a potent effect on adipogenic processes in subcutaneous adipose tissue in 
weight stable humans. 
Although our findings suggest exercise may not impact adipose tissue fibrosis or 
adipogenesis in weight stable human subjects, prior exercise does appear to suppress subsequent 
lipolytic activity. Our findings that acute exercise lowered ex vivo lipolytic response is in 
agreement with previous work reporting a reduction in beta adrenergic stimulated lipolysis in 
subcutaneous adipose tissue one hour after a moderate session of aerobic exercise (56). The 
reduced lipolytic sensitivity to catecholamines after a single session of exercise that we observed 
may be metabolically beneficial by reducing systemic release of fatty acids into the circulation 
that are detrimental to whole-body insulin sensitivity at high levels for extended periods of time. 
Experiments performed in vitro and in situ (i.e., microdialysis) have demonstrated that a 
sustained exposure to catecholamines can desensitize the adrenergic lipolytic response (57, 58), 
so the lower lipolytic response measured 1h after acute exercise may be a consequence of 
elevated plasma catecholamines that occur during the exercise session. Prolonged stimulation of 
beta adrenergic receptors cause inhibition of the G-protein coupled receptor (GPCR) signaling 
cascade to a subsequent exposure of agonists (59) and is thought to be an important 
physiological feedback mechanism that protects cells from receptor overstimulation. The process 
of the desensitization is not fully elucidated, but involves a complex regulation of various 
phosphorylation sites on the receptors that control the internalization of the receptors to the 
cytoplasm (60). With extended exposure to catecholamines, the beta adrenergic receptors are 
retained in the cytoplasm and do not return to the cell membrane, thus reducing the beta 
adrenergic signaling response to a second agonist exposure. In contrast to the acute exercise 
effects, endurance exercise training without weight loss does not appear to change lipolytic 
sensitivity when measured at least a few days after the last exercise training session (61). Our 
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findings that in vitro lipolytic response to isoproterenol was similar between ACTIVE and SED 
supports this notion that adaptations to chronic exercise training, do not impact adrenergic 
lipolytic response. We also did not find any differences in basal lipolysis between regular 
exercisers and non-exercisers. 
While some studies have reported higher or lower basal lipolytic rates after exercise training, 
differences in subject population (i.e. lean, obese, T2D), timing of sample collection, and 
methodologies may account for some of this disparity. For example, the effect of exercise 
training on lipolytic response to catecholamines is confounded by weight-loss that often 
accompanies endurance exercise programs (62, 63). Weight loss and a resultant loss of body fat 
mass (and smaller adipocyte diameter) is known to augment lipolytic sensitivity to 
catecholamines (64-66). 
Several studies have reported that exercise training lowers adipose tissue inflammation in 
humans, which may lead to improved whole body metabolic outcomes (26, 27). Unfortunately, 
most of these exercise studies were confounded by weight-loss, which is known to have a robust 
impact on lowering adipose tissue inflammation (25, 27, 28). The independent effects of exercise 
on adipose tissue inflammation are far less clear. Recent evidence from some animal studies 
suggest a beneficial effect of both acute and chronic exercise on inflammation and metabolic 
function of adipose tissue independent of weight loss and adiposity (31, 34). Our finding that 
ACTIVE had a higher expression of IL6 in the CD14+ fraction of the adipose tissue compared 
with SED suggests that habitual exercise training may alter the inflammatory state of the adipose 
tissue resident immune cells. In agreement with our findings, IL6 expression and signaling 
within adipose tissue has previously been found to be upregulated after an exercise session in 
mice (31), with implications for altering the metabolic function of the adipose tissue. This 
finding is intriguing since IL6 has been implicated as being important for shifting the 
inflammatory status in macrophages from a more pro-inflammatory “M1” phenotype to a more 
alternatively activated “M2” state. However, since we did not find changes in the mRNA 
expression of IL6 or other markers of inflammation in adipose tissue after a single session of 
exercise, it remains unclear why ACTIVE would have a higher IL6 expression in their CD14+ 
fraction.  
It is well-known that most of the improvements in insulin sensitivity associated with 
exercise are associated with the most recent exercise session, and removal of exercise for as little 
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as 48 hours can return insulin sensitivity to levels similar to untrained individuals (67-69). 
Therefore, because our ACTIVE subjects performed the OGTT three days after their most recent 
exercise session, as expected glucose tolerance was indeed similar between ACTIVE and SED. 
Our data does not necessarily mean that exercise training will not have beneficial effects on 
adipose tissue that would translate into measurable improvements in metabolic health. It is 
important to note that other than being overweight and/or mildly obese, our SED subjects were 
still in general good health, and thus, the effect of exercise training in our ACTIVE group may 
be very hard to detect when compared with our relatively healthy SED cohort. It may also be 
possible that the metabolic benefits of exercise on adipose tissue are only measurable when 
combined with weight gain. Alterations in adipose tissue observed in studies from Kawanishi et 
al. (32, 33)occurred when exercise was combined with weight gain. Perhaps the exercise 
stimulus “primes” the adipose tissue for healthful adaptability to weight gain, but these 
adaptations only occur when nutrient excess also stimulates processes to store more lipids.  
Findings from this study expand on the limited knowledge of the effects of exercise on 
adipose tissue structure and function in humans, however there are several limitations. The 
mRNA expression data in this study provide valuable insight, especially when examining the 
acute response one hour after a session of exercise, where adaptive responses in protein 
abundance would likely not be measurable. Notably, many adaptations to exercise result from 
the cumulative effect of transient increases in mRNA transcripts that occur with each exercise 
bout, eventually leading to an accumulation of adaptive proteins (4, 70). However, clearly many 
aspects of metabolic processes and cellular function are regulated at the level of protein 
translation and post-translational modifications, without a direct link to changes in the levels of 
mRNA (71). Unfortunately, limitations in tissue sample yield prevented us from making 
measurements at the protein level. We also acknowledge that the number of subjects in this study 
is small, and thus, small changes in metabolic outcomes in adipose tissue may have been missed, 
especially with the very large variability in adipose tissue outcomes in humans. However, we 
feel that this data set provides a solid foundation for further research focused on the aspects that 
have shown promise for responding to exercise ( e.g., angiogenesis and macrophage 
polarization). Additionally, we used a “conventional” exercise stimulus of 1hr at ~65% 
VO2peak, but there may be very different responses to different exercise modalities and 
intensities (i.e. high-intensity interval training, strength training).  
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In conclusion, our study suggests that a single session of aerobic exercise may lead to an 
increase in the mRNA expression of VEGFA, the primary mediator of angiogenesis, in adipose 
tissue. This response may lead to an increase in adipose tissue capillarization as evidenced by the 
elevated mRNA expression of CD31. We did not find an effect of exercise on markers of 
adipogenesis or fibrosis. Exercise training may also play a role in alternative activation of 
immune cells, as habitual exercisers had a higher mRNA expression of IL6 in the CD14+ 
enriched fraction of their adipose tissue compared with their sedentary counterparts. Our ex vivo 
experiments demonstrate that a single session of exercise can transiently reduce beta adrenergic 
stimulated lipolysis in the post-exercise period, however, there is no effect of exercise training. 
Further studies are needed to examine the effects of exercise on adipose tissue structure and 
function, especially to investigate whether any changes in the adipose tissue measurably improve 
metabolic health in obesity. Our data suggests that exercise may alter adipose tissue health and 























symbol Protein encoded 
PPARG proliferator-activated receptor gamma (PPARγ) 
SREBP1C sterol regulatory element-binding protein 1 (SREBP1c) 
CEBPA CCAAT/enhancer-binding protein alpha (CEBPα) 
GPAT1 glycerol-3-phosphate Acyltransferase-1 (GPAT1) 
DGAT1 diacylglyceride acyltransferase 1 (DGAT1) 
ATGL adipose triglyceride lipase (ATGL) 
HSL hormone-sensitive lipase (HSL) 
FABP4 fatty acid binding protein 4 (FABP4) 
PLIN1 perilipin 1 (PLIN1) 
COL6A1 collagen VI  
COL1A1 collagen I  
VEGFA vaascular endothelial growth factor (VEGF) 
HIF1A hypoxia-inducible factor (HIF1α) 
PECAM1 cluster of differentiation 31 (CD31) 
MCP1 monocyte chemoattractant protein-1 (MCP-1) 
TNFA tumor necrosis factor alpha (TNFα) 
NLRP3 NOD-like receptor family, pyrin domain containing 3 (NLRP3) 
IL1B interleukin-1 beta (IL1β) 
ITGAX "M1" macrophage marker CD11c 
MRC1 "M2" macrophage marker CD206 
CD163 "M2" macrophage marker CD163 
SLC2A1 Glucose transporter 1 (GLUT1) 
 














   
 SED ACTIVE 
Sex (M/F) (5/7) (3/5) 
Age 27±2 27±1 
Body mass (kg) 82±3 80±3 
BMI (kg/m2) 27±1 29±1 
Body fat (%) 31±2 29±2 
FM (kg) 26±2 24±3 
FFM (kg) 57±3 57±3 
VO2peak (ml/kg FFM/min) 42±2 52±3* 
Matsuda ISI 8.2 ± 1.4 5.6 ± 0.3 
HOMA-IR 1.3 ± 0.2 1.6 ± 0.1 
Glucose AUC 868 ± 56 972 ± 60 
Insulin AUC 8647 ± 1483 11323 ± 1101 
* p<0.05 compared with SED. 
Data presented as Mean ± SD.   
 
































































Figure 5-2: mRNA expression of factors related to angiogenesis, capillarization, and 
hypoxia in the whole adipose tissue homogenate in SED compared with ACTIVE both 
before (PRE) and 1hr after exercise (POST).  Expression values were normalized to the 
mean of the housekeeping genes PPIA and B2M. Data expressed as MEAN ± SD. 

































Figure 5-3: mRNA expression of factors related to 
inflammation in the whole adipose tissue homogenate in 
SED compared with ACTIVE both before (PRE) and 1hr 
after exercise (POST).  Expression values were normalized 
to the mean of the housekeeping genes PPIA and B2M. 































Figure 5-4: mRNA expression of factors related to 
inflammation in the CD14+ enriched fraction in SED 
compared with ACTIVE both before (PRE) and 1hr after 
exercise (POST).  Expression values were normalized to 
the mean of the housekeeping genes PPIA and B2M. Data 




























Figure 5-5: Glycerol release measured in mature adipocytes (A and C) and adipose tissue 
explants (B and D) taken before exercise (PRE) and 1hr after exercise (POST).  Basal 
conditions (Basal) had no stimulation while ISO had incubation in isoproterenol.  Data 





























Figure 5-6: mRNA expression of factors related to related to lipolysis (ATGL, HSL), 
esterification (GPAT, DGAT), lipid storage (PLIN1, CIDEA), or lipogenesis/adipogenesis 
(SREBP1C, PPARG) in mature adipocytes extracted from adipose tissue samples collected 
before or after exercise in SED compared with ACTIVE both before (PRE) and 1hr after 
exercise (POST).  Expression values were normalized to the mean of the housekeeping 































Figure 5-7: mRNA expression of factors related to extracellular matrix in the 
whole adipose tissue homogenate in SED compared with ACTIVE both before 
(PRE) and 1hr after exercise (POST).  Expression values were normalized to the 
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Obesity has become a major health issue in the United States with an annual healthcare cost of 
~$147 billion. The development of insulin resistance, which is central to metabolic diseases such as type 
2 diabetes and cardiovascular disease, is common in obesity. With over one-third of the United States 
population considered obese, with no signs of declining, it is important to understand the relationship 
between obesity and the development of insulin resistance for the development of targeted treatments that 
may alleviate insulin resistance and thus, obesity-related disease. My dissertation work primarily focused 
on the role of subcutaneous adipose tissue in metabolic health since it is now known that adipose tissue 
“health” and metabolic function is associated with  obesity-related insulin resistance. Alterations in 
various factors and processes within adipose tissue, such as lipid storage, inflammation, extracellular 
matrix composition and structure, adipogenesis, and angiogenesis, have all been implicated in 
determining the magnitude of many obesity-related metabolic health complications, including insulin 
resistance. Furthermore, although exercise is often prescribed to improve metabolic health in obesity, it 
remains unknown whether exercise causes adaptations in adipose tissue structure and function that may 
contribute to improvements in whole-body metabolic health. The overall objective of my dissertation 
studies was to assess how subcutaneous adipose tissue may contribute to whole-body metabolic outcomes 
in obesity, and whether exercise can modify adipose tissue in a manner that may lead to improved overall 
metabolic health. 
Together, my dissertation studies have fulfilled this purpose and provided insight into 
important aspects of adipose tissue physiology and biology that may translate to whole-body 
metabolic health outcomes. More specifically, my dissertation studies have demonstrated: A) 
basal fatty acid flux from subcutaneous adipose tissue is an important determinant of insulin 
resistance and metabolic health (STUDY 1), B) adipose tissue from obese adults who maintain 
relatively low rates of fatty acid flux have alterations in factors related to triglyceride storage 
(higher) and release (lower), lower fibrosis, and lower markers of activation of some key 
inflammatory pathways (STUDY 2), and, C) endurance exercise may modify adipose tissue by 
triggering events related to an increase in angiogenesis and capillarization. (STUDY 3). Further 
details of the findings in each of these studies are described and discussed in detail in Chapters 3-
5. In this overall summary, I will provide an integrative discussion on the collective significance 
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and importance of the findings of my dissertation and how they relate to existing knowledge in 
the field. 
It has become very evident that the adipose tissue is a far more complex tissue than its 
classical description as simply a benign storage site for surplus energy. Adipose tissue constitutes 
adipocytes, extracellular matrix components, blood vessels, immune cells, and adipose stem 
cells, all of which can respond markedly to weight gain or loss. The integrative responses and 
interactions between adipocytes and other cells within adipose tissue can impact metabolic 
homeostasis, especially in the context of nutrient excess and obesity. Biological pathways related 
to inflammation, fibrosis, adipogenesis, angiogenesis, hypoxia, and lipid metabolism within 
adipose tissue are all implicated as important pathways impacting whole body metabolic 
outcomes. Alterations in one or more of these pathways may ultimately effect the lipid storage 
capacity of adipose tissue, leading to excessive systemic availability of fatty acids, which is 
known to cause metabolic abnormalities in other peripheral tissues such as skeletal muscle, liver, 
and pancreas. Because excessive mobilization of fatty acids into the systemic circulation is 
responsible for inducing profound systemic insulin resistance (1-6), one major theme of my 
dissertation studies targeted adipose tissue’s role in storing and releasing fatty acids.  
Findings from my dissertation support the “adipose tissue expandability hypothesis” 
which suggests that the ability to appropriately expand adipose tissue to accommodate excess 
nutrients is key to the maintenance of metabolic health. Although it has been well established 
that increasing systemic fatty acid mobilization induces systemic insulin resistance (1-6), 
STUDY #1 of my dissertation expands on these findings by demonstrating that the magnitude of 
basal fatty acid mobilization (FA Ra) from adipose tissue in obese adults was proportional to 
their insulin resistance. In other words, obese adults who maintain a lower FA Ra can preserve 
normal insulin sensitivity, despite having excess fat mass. This maintenance of a relatively low 
FA Ra in STUDY #1 was also accompanied by attenuated markers of inflammatory signaling in 
skeletal muscle. These findings from STUDY #1 provide valuable insight into why some obese 
adults may be protected from developing insulin resistance. However, without adipose tissue 
biopsies in STUDY #1, it was not possible to ascertain mechanisms that may underlie the 
relatively low fatty acid mobilization in the NORM-Si cohort. Therefore, to follow-up on the 
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important findings in STUDY #1, STUDY #2 was primarily designed to address what factors 
underlie the variability in fatty acid mobilization in otherwise similar obese adults.  
A majority of systemic fatty acids are derived from subcutaneous adipose tissue, and fatty 
acid flux from adipose tissue is ultimately controlled by the coordination of triglyceride 
hydrolysis, esterification, and fatty acid trafficking. An imbalance in these processes could result 
in high rates of fatty acid flux and impaired metabolic health. In STUDY #2, adipose tissue from 
obese adults who had low FA Ra had lower basal phosphorylation of HSL (p-HSLser660) 
suggesting lower catecholamine induced lipolytic activity. In addition, findings from STUDY #2 
were the first to our knowledge to demonstrate obese adults with low FA Ra have an elevated 
abundance of GPAT, an important enzyme for catalyzing the first step of committing a fatty acid 
to be stored as a triglyceride. Our human data coincides with in vitro work demonstrating 
increased triglyceride storage with GPAT overexpression. These data from STUDY #2 expand 
on our findings from STUDY #1 about the link between fatty acid flux and insulin sensitivity, 
and further advance our understanding about the association between adipose tissue metabolic 
function and metabolic health by demonstrating factors regulating lipolysis and esterification in 
adipose tissue may be important for protecting some obese adults from insulin resistance. 
Components of adipose tissue structure can also contribute to the tissue’s ability to store 
fatty acids. The extracellular matrix (ECM) provides a structural and signaling network for the 
adipose tissue while the capillary network within adipose tissue is necessary for nutrient and gas 
exchange in the tissue. Alterations in the adipose tissue ECM and/or vasculature may impact the 
capacity of the adipose tissue to control fatty acid flux in obesity, as well other important aspects 
related to metabolic health (e.g., hypoxia, inflammatory status, etc.). The gene ontology 
outcomes in STUDY #2 revealed that obese adults with low FA Ra had lower enrichment of 
pathways related to ECM structure, organization, and disassembly in their subcutaneous adipose 
tissue compared with obese adults with elevated FA Ra, supporting that ECM structure in 
adipose tissue is important for whole body outcomes. To our knowledge, these are the first data 
in human adipose tissue to link elevated markers of fibrosis in subcutaneous adipose tissue with 
elevations in FA Ra and adds an essential link in understanding the relationship between adipose 
tissue fibrosis and whole-body insulin sensitivity. Collagen VI is one of the most prominent 
collagens expressed in adipose tissue, and absence of collagen VI in adipose tissue of mice 
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results in improved whole body metabolic health on a high fat diet. Interestingly, in these mice, 
absence of collagen VI lead to an increased hypertrophy of the adipocytes, suggesting that 
elimination of this key component of the ECM may allow for adipocytes to expand with less 
restriction, leading to greater lipid storage, and thereby may help protect against ectopic lipid 
deposition in other tissues. We measured mRNA expression of collagen VI in STUDY #2 and 
found that it was proportional to the degree of FA Ra, supporting the notion that lower ECM 
deposition and assembly in obese adipose tissue can have a protective effect on whole body 
metabolic health. Unfortunately, without adipose tissue samples for histological analysis in 
STUDY #2, we cannot confirm that lower collagen VI expression was related to greater 
hypertrophy of adipocytes. We did not find any evidence that adipogenic or angiogenic processes 
were contributing to differences in metabolic health among our obese subjects in STUDY #2. 
Importantly, our subjects in STUDY #2 were weight stable and all measurements were made in 
the post-absorptive state, thus there was no stimulus for adipose tissue expansion. We postulate 
that differences in markers for these processes may only be apparent during a period of nutrient 
excess and weight gain when the adipose tissue is stimulated to expand, and not during 
basal/weight-stable conditions. Regardless, STUDY #2 of my dissertation helps advance our 
understanding about the potential impact of the ECM in human adipose tissue on whole body 
metabolic health in obesity. 
In obesity, there is also an increase in inflammation within the adipose tissue that can 
disrupt metabolic function locally as well as systemically. Inflammation is tightly linked to poor 
metabolic outcomes, but it is also highly proportional to the degree of fibrosis and hypoxia in 
adipose tissue. Elevated inflammation occurs via proliferation and altered activation of resident 
immune cells as well as through recruitment and infiltration of more immune cells. The reduced 
markers of fibrosis in subcutaneous adipose tissue of our insulin sensitive obese adults in 
STUDY #2 led us to hypothesize that we would also observe lower markers in inflammation in 
their adipose tissue. However, GO analysis of the microarray data in STUDY #2 indicated that 
obese adults with low FA Ra had enrichment of pathways related to antigen receptor-mediated 
signaling, defense response, and lymphocyte differentiation, suggesting greater immune activity 
in their adipose tissue compared with obese adults with elevated FA Ra. The immune response is 
highly complex, and while it is tempting for us to speculate whether the inflammatory 
environment in the adipose tissue is simply “pro-inflammatory” or “anti-inflammatory”, the 
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immune activity in the adipose tissue can be far more nuanced. Most studies primarily focus on 
the role of macrophages in regulating inflammation in the adipose tissue but there are certainly 
other infiltrating immune cells dictating the inflammatory response. We found many of the most 
highly upregulated genes to be associated with T cells and antigen-receptor signaling, and it is 
now appreciated that changes in CD4+ and CD8+ T cells can dictate macrophage recruitment 
and inflammatory response to obesity. The enrichment of the lymphocyte differentiation 
pathways may be from propagation of the more “protective” CD4+ T cells that may dampen 
metabolic disturbances with increased fat mass. However, without specific cell sorting it is 
impossible for us to conclusively determine this. Obese adults with low FA Ra also had lower 
activation of the SAPK/JNK pathway that is important for the activation and inflammatory status 
of myeloid cells. Findings from STUDY #2 suggests that the relationship between overall 
inflammatory status of the adipose tissue and whole body metabolic health is complex and may 
not be a simple linear relationship between classic markers of inflammatory status and metabolic 
health. The enhanced insulin sensitivity observed in some obese adults in STUDY #1 and 
STUDY #2 may be partially dictated by “protective” immune responses in adipose tissue that 
preserve adipose tissue function in the face of obesity. 
With STUDY #2 identifying factors in adipose tissue that may contribute to metabolic 
outcomes in obesity, the next goal of my dissertation was to determine if an intervention can 
modify adipose tissue to develop a more “healthful” phenotype. It is well-known that weight loss 
interventions can improve adipose tissue and whole body metabolic health, however, little is 
known about the direct effects of exercise, independent of weight loss. STUDY #3, was designed 
in part to test whether endurance exercise can impact adipose tissue structure and function in a 
manner that would resemble the phenotype from metabolically healthy obese adults in STUDY 
#2. However, in general we did not find an effect of acute or chronic exercise on the mRNA 
expression of factors important for metabolic health that we identified in STUDY #2, such as 
lipid handling factors (i.e. HSL, GPAT) or ECM (i.e. COL6A1). Importantly, however, our main 
finding from STUDY #3 demonstrating that a single session of exercise stimulated an increase in 
mRNA expression of VEGFA, which is considered a primary regulator of angiogenesis, suggests 
that exercise may trigger an upregulation of angiogenic pathways in adipose tissue. 
Accompanying this increase in VEGFA expression, we also found an elevated gene expression 
of CD31 (a marker of endothelial cells) in adipose tissue from habitual exercisers.  We interpret 
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this to suggest that the repeated transient elevation in VEGFA signaling that regularly occurs in 
the habitual exercisers induced structural adaptation to the adipose tissue vasculature (i.e., 
increased adipose capillarization). We also found a higher mRNA expression of IL6 in the 
CD14+ enriched fraction of the adipose tissue and we are intrigued by this finding since IL6 
signaling in myeloid cells can be an important mechanism for promoting alternative activation or 
“anti-inflammatory” properties in immune cells. However, there were no significant changes in 
the expression with an acute bout of exercise so it remains unclear exactly what may be causing 
a sustained elevation in IL6 mRNA in the immune cells. While it is tempting to speculate that 
increased capillarization and possible changes in immune cell activation may improve metabolic 
outcomes in obesity, it remains possible that these changes in adipose tissue will not have a 
measurable impact on overall metabolic health without a change in fat mass. Regardless, the data 
from STUDY #3 demonstrates that exercise can initiate angiogenic processes and potentially 
induce alternative activation in immune cells in subcutaneous adipose tissue. By increasing 
angiogenesis with regular exercise, the adipose tissue may exhibit improved lipid storage 
capacity through reductions in hypoxic stress. Further, exercise may initiate alternative activation 
of immune cells and alter the inflammatory state of the adipose tissue. STUDY #3 demonstrated 
that exercise may improve mechanisms of adipose tissue metabolic health, but these adaptations 
do not mimic the same mechanisms and pathways we observed in STUDY #2 that protected 
adipose tissue and metabolic health in some obese adults. 
Together, my dissertation studies demonstrate that the health and function of adipose 
tissue is an important mediator of overall metabolic health in obesity and that exercise may be a 
useful intervention for improving adipose tissue structure and function. The capacity of the 
adipose tissue to sequester and store excess nutrients and protect other tissue depots from ectopic 
lipid deposition is key for protection against insulin resistance in the face of obesity. Various 
pathways including reduced lipolysis, increased esterification, reduced ECM enrichment, and 
altered immune activity were related to maintenance of low fatty acid flux in insulin sensitive 
obese adults. In addition, exercise may be a useful intervention to improve adipose tissue 
metabolic health by increasing capillarization and reducing metabolic dysfunction related to 
hypoxic stress. My dissertation has provided exciting new information regarding adipose tissue 




Obesity is often accompanied by the development of insulin resistance, which is central to many 
chronic cardio-metabolic diseases, such as type 2 diabetes and cardiovascular disease. These diseases are 
associated with lower quality of life and increased mortality. In addition, the economic burden and 
national healthcare costs of obesity-related disease is enormous, with more than 20% of national health 
care expenditures directed toward treating obesity-related illness and disease.  It is important to find 
therapeutic targets and treatments that can prevent or reverse insulin resistance, which would not only 
reduce the economic burden associated with obesity, but even more importantly, would mitigate the 
tremendous personal challenges to many of those who suffer from obesity-related diseases. My 
dissertation provides new information regarding adipose tissue biology and the control of metabolic 
outcomes in obese adults.  In particular, STUDY #1 and #2, demonstrated that the rate of fatty acid 
mobilization from adipose tissue was directly associated with insulin resistance, and obese adults with 
high rates of fatty acid mobilization exhibit alterations in factors related to lipid handling, inflammation, 
and fibrosis in adipose tissue. To follow-up on the findings, future work could focus on clarifying the role 
of fibrosis in the control of lipid handling in adipose tissue. Examining the relationship of adipose tissue 
fibrosis and fatty acid mobilization in lean adults could help determine if this relationship occurs before 
the onset of obesity, and whether the levels of fibrosis are predictive of future metabolic outcomes with 
controlled weight gain studies. These types of studies may provide a timeline of adaptations in the 
adipose tissue to help understand of the excessive fibrosis is a cause or a consequence of the elevated fatty 
acid mobilization. Further measurements to verify our findings are needed as well, such as histological 
quantification of ECM in the adipose tissue. In addition, in STUDY #3, it was demonstrated that exercise 
training may increase angiogenic processes and lead to an increase in capillarization in adipose tissue. 
These adaptations may “prime” adipose tissue for improved metabolic responses during periods of weight 
gain by mitigating hypoxic conditions associated with expanding fat mass. Future studies could be 
designed to examine if exercise can mitigate poor metabolic responses during periods of weight gain. We 
hypothesize that adipose tissue adaptations and the regulation of fat storage in response to overeating in 
people who exercise regularly may differ considerably when compared with non-exercisers, resulting in 
more favorable health outcomes in the exercisers despite the same degree of weight gain.  Furthermore, 
histological examination of the adipose tissue should be used to verify that exercise training does indeed 
increase capillary density in the adipose tissue. The data from my dissertation projects, combined with 
follow up mechanistic analysis, could allow for targeted treatments to prevent excessive fatty acid 
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